The roster is familiar: revenue cycle, pharmacy, ambulatory operations, clinical operations, senior executives. The recommendation to offer the therapy came from the clinical service line leader and arrives with the clinical case already made. What this room decides is something else. Whether the therapy is delivered in a hospital outpatient department that carries 340B benefit, or at another site of service. Occasionally the answer is that the organization will not offer it at all, when it cannot be made to work financially anywhere. And sometimes the question runs the other direction: whether an existing site should be converted into a hospital outpatient department so that it carries the benefit.

The number driving the decision sits in the pharmacy line, labeled 340B benefit. It is quantified partly to understand what the program contributes and partly to understand how much the service line’s profitability depends on it. It stays out of the service line pro forma and out of the financial reporting. The figure shaping where a patient will receive treatment lives in a document separate from the one recording the decision.

I have been in rooms like that one. The people in them are conscientious and the work is ordinary, and the meeting sits on a standing calendar because this decision comes up several times a year, every year, at systems across the country.

That room has always run on a number the government never actually quantified. Three weeks ago it measured it. Medicare had spent most of a decade declining to ask hospitals what they pay for the drugs they buy, and the answer, published on July 7 inside a proposed payment rule written so that few people outside hospital finance would ever get through it, was that drugs acquired through the 340B program cost hospitals 33.4 percent below the average sales price, the benchmark Medicare uses to set what it pays. Drugs acquired outside the program cost 2.7 percent above it. Over that same window, Medicare was reimbursing those same hospitals at the benchmark plus six percent. In round numbers, the hospital buys at sixty-seven cents and is paid a dollar six.

That difference has a name in the trade. It is the spread, and it is worth being clear about something before going further: the spread is not an abuse of the program. The spread is the program. Congress built 340B in 1992 by requiring drug manufacturers, as a condition of participating in Medicaid, to sell certain outpatient drugs to safety-net providers at a deep discount. It attached no appropriation, and it attached no requirement that the resulting margin be traced to a low-income patient or reported to anyone. That last line should sound familiar to anyone who read last week’s piece: the reporting requirement is missing in the same place, for the same institutions.

Two honest qualifications. Thirty-three percent off acquisition is not thirty-three percent to the bottom line, because split-billing software, third-party administrators, contract pharmacy dispensing fees and the compliance staff the program requires all come out of it first. And the six percent is a statutory figure; after sequestration the effective rate lands closer to four and a third. The spread survives both. It is smaller than the headline and it is still the largest reliable margin in most hospital pharmacies.

The argument worth having about that conference room is not the one either industry lobby is making. The pharmaceutical industry’s version is that 340B has become a scam. The hospital associations’ version is that it is working as intended. Both are arguments about the average. Look instead at the distribution, because the two ends of it are not the same room, and almost everything interesting about this program lives in the distance between them.

It helps to clarify the size of the program first. In calendar year 2024, covered entities purchased $81.4 billion in discounted drugs, up 23 percent in a single year, and disproportionate share hospitals, the large facilities that qualify by treating a high proportion of low-income patients, accounted for nearly 79 percent of it. That growth did not come from a sudden expansion of the uninsured population. It came from institutions doing what financially rational institutions do. The Congressional Budget Office found that the number of off-site outpatient clinics registered in the program grew from roughly 6,100 in 2013 to 27,700 in 2021, a great many of them in affluent, commercially insured markets. Contract pharmacy arrangements went from fewer than 1,300 locations in 2010 to roughly 31,600 today, spanning something close to 240,000 separate covered-entity contracts. A contract pharmacy is a retail pharmacy that dispenses 340B-priced drugs on a hospital’s behalf and splits the spread with it, which is why a single hospital can have hundreds of them.

Those numbers describe a peak rather than a trend. Since 2020 a long list of manufacturers has restricted contract pharmacy shipments outright, and the fight has now moved to rebate models and state protection laws, with the federal circuits now split on whether those state laws survive. The restrictions are themselves evidence that the extraction is real enough for manufacturers to have spent six years and considerable money trying to stop it.

Here is why the geography matters. The spread on a drug is proportional to the drug’s price and to what the payer reimburses, which means the program pays best on expensive drugs given to commercially insured patients. Oncology sat at the top of that list for a long time, and the pattern is visible in the data: researchers at the USC Schaeffer Center found Part B oncology spending per Medicare beneficiary running substantially higher at 340B sites than at comparable non-340B sites, with 340B eligibility associated with a roughly 90 percent increase in hematology-oncology claims. Association is not attribution, and site-of-care migration and referral concentration both push in the same direction. But site-of-care migration is not a statistical artifact. It is a decision, made on a standing calendar, by the room described at the top of this piece. The researchers are measuring the residue of thousands of those meetings.

Set that beside what the Government Accountability Office has been reporting for years. In a review of 55 covered entities, a sample GAO itself cautions does not generalize to the program, 30 offered discounts to low-income or uninsured patients at some or all of their contract pharmacies. Just over half. The important part is that the other twenty-five broke no rule, because no rule required them to do otherwise. That is the finding. Not that covered entities broke a promise, but that Congress never asked for one.

Now the other end of the distribution. A twenty-five-bed critical access hospital in a rural county qualifies for 340B on different terms than an urban system does, and depends on it differently. Cost-based Medicare reimbursement sounds like it should cover cost, but it does not because it pays a percentage of allowable costs on Medicare patients only and leaves the rest of the building uncovered. The 340B margin fills part of that gap. And here is the uncomfortable part, the one that complicates my own frame: the rural hospital’s margin comes from the same place the suburban system’s does, from commercially insured patients and retail scripts run through a contract pharmacy. The mechanism is identical at both ends. Only the use of the money differs, and only one end has the scale to build a service line designed around it.

The clearest evidence of how thin the rural end of the spectrum runs sits in a contradiction Congress has left in place since these facilities first became eligible in 2023. Rural Emergency Hospitals, the designation created specifically to keep small rural facilities from closing, are statutorily ineligible for 340B. A hospital that converts in order to survive loses the program in the same transaction. The Rural 340B Access Act, introduced in January of 2025, would fix exactly this. It has sat in committee since.

The loss compounds from there, running in a loop rather than a chain. A thin margin makes an oncology service line hard to sustain; losing the line removes the highest-spread category from the hospital’s 340B book; and that thins the margin that sustains everything else. Between 2014 and 2023, 424 rural hospitals stopped providing chemotherapy services. The wrinkle worth naming is that critical access hospitals, rural referral centers and sole community hospitals are excluded from 340B pricing on orphan-designated drugs, which covers a good deal of modern oncology, so the rural end of this ledger was thinner than the urban one by definition. Set the two ends beside each other and the shape is hard to miss. In one room the question is which new therapy to offer where. In the other, the question was whether chemotherapy could continue at all, and for 424 hospitals the answer was no. What that produces is a patient with a curable cancer driving ninety miles each way, every three weeks, for a cycle that used to be given a few minutes from home.

The strongest objection to all of this is correct as far as it goes. Cross-subsidization is how safety-net hospitals have always worked. Revenue earned on commercially insured patients has funded uncompensated care for as long as there have been hospitals, and demanding a dollar-for-dollar accounting that ties each discounted vial to a specific charity prescription misunderstands how hospital finance operates. The honest question was never whether every 340B dollar buys an uninsured patient’s medicine. It is whether the institution’s capacity to serve underserved patients survives without the program, and for a great many covered entities, particularly rural ones, the margin is the institution. The evidence on the other side is mixed rather than damning. A February preprint, not yet peer reviewed and written by authors with a stated critical posture, found 340B hospitals providing somewhat less charity care as a share of operating expenses than non-340B hospitals, 2.16 percent against 2.82. Two scoping reviews, in the Milbank Quarterly and JAMA Health Forum, reached the same unsatisfying place: real revenue, expanded services, inconsistent evidence that the revenue specifically reaches low-income patients.

There is one more thing worth holding onto, and it is the reason anyone on the provider side, at the bedside or in the budget meeting, can cite the GAO findings without becoming a pharmaceutical talking point. There is no appropriation and no line in a federal budget. The discount comes out of manufacturer revenue. The spread, though, is paid on the claim, which means commercial premiums and Medicare coinsurance fund it, and manufacturers argue the cost reappears in list prices, an argument that deserves a hearing it rarely gets from our side. What remains true is that the first-order incidence sits with an industry that is not the patient in the bed. That distinction changes the weight of the critique considerably, and it is what makes an honest accounting possible from the provider side at all.

Which brings the argument back to the proposed rule, and to the part that will be misread. Medicare is not changing 340B. The discount, the eligibility rules and the ceiling price all live at HRSA and none of them change. What Medicare controls is what it pays, and the proposal is to reimburse 340B-acquired drugs at the benchmark minus 33.4 percent rather than the benchmark plus six, which removes the spread on the Medicare portion of a hospital’s drug volume. Because the change has to be budget neutral by statute, the roughly $4.55 billion it recovers gets handed back to hospitals paid under the outpatient system as an 8.44 percent increase in what Medicare pays for non-drug services. Follow the money and the transfer is the story. It moves away from hospitals in the program and toward hospitals generally, which makes hospitals that were never in 340B the net winners, and which makes procedural and surgical service lines at those hospitals the quiet beneficiaries of a rule everyone will describe as a drug cut.

Being specific about what the rule reaches matters, because the piece would be wrong otherwise. The largest spread sits on commercially insured patients, and Medicare cannot touch that book. A rule aimed at the top of the distribution reaches only the part of it Medicare pays for.

Go back to the conference room, though, because this is where the two threads meet. Medicare has been narrowing the payment advantage of hospital outpatient status for years, one service line at a time. Clinic visits went to a physician-office-equivalent rate in 2019. Drug administration followed, effective this past January, at grandfathered off-campus departments. Imaging without contrast is the one proposed for 2027. Each of those narrows what a hospital earns for the service of delivering an infusion. What survived all of it was the drug line, which is to say the 340B spread, and the drug line is the reason the conversion question keeps coming back to that room. A March court decision made it easier still, vacating HRSA’s requirement that a new outpatient site appear on the Medicare cost report before it could buy at 340B prices. The government has appealed. So the honest way to read this proposal is that Medicare, having spent a decade trimming the reward for delivering care in a hospital outpatient department, is now going after the one part of that decision that still pays.

This is also the second time Medicare has tried the 340B piece. In 2018 it cut 340B drug payment to the benchmark minus 22.5 percent, and in 2022 a unanimous Supreme Court threw the cut out, not because a differential rate was forbidden but because the agency had varied the rate by hospital group without the acquisition-cost survey the statute requires before it may do so. This time the survey came first. That is what the 33.4 percent figure is: the evidentiary record the Court said was missing, built and published before the rate was proposed. Hospitals are also still absorbing the remedy from the first attempt, a reduction to non-drug payments that this same rule proposes to raise from half a percent to three. The legal armor is different now, and hospitals planning around a second Becerra are planning around the wrong case.

Now the part I had wrong when I started writing this, and the part most coverage will likely get wrong too. The rule does not fall evenly, and it does not fall on the bottom of the distribution at all. Critical access hospitals are excluded from the outpatient payment system by regulation and paid on cost, so the cut cannot reach them, and neither can the 8.44 percent offset. Rural sole community hospitals, children’s hospitals and PPS-exempt cancer hospitals were carved out of the 2018 cut, and the current proposal carries those exemptions forward, leaving them at the benchmark plus six while they collect the service-payment increase alongside everyone else. They come out ahead. CMS says in the same section that it may revisit the rural exemption in future rulemaking, and it is taking comment on all three. The protection is real and it is discretionary.

Sit with what that means. The payment system has learned to tell the two rooms apart. It sorts by hospital class, protects the facilities where the program is most clearly working as intended, and lands the cut on the large disproportionate share systems that capture most of the spread. The program itself still makes no such distinction. 340B allocates its benefit in proportion to commercially insured volume and contract pharmacy scale, which is very nearly the inverse of safety-net need, and it has done so for thirty-four years. Medicare figured out in one rulemaking cycle what the statute has never been amended to see.

Whether any of this is a rounding error or a service-line decision at your institution comes down to three numbers your chief financial officer already has: the share of your 340B margin that comes from Medicare rather than commercial payers, the share that comes from oncology, and your non-drug outpatient volume. The first sets your exposure, the second sets your concentration, and the third sets how much of the offset comes back to you. If you are at a hospital paid under the outpatient system with a large Medicare oncology book, you are the target. If you are at a critical access hospital, a children’s hospital or a rural sole community hospital, you are not, and the more useful question is what the increase does for the service lines you run. Comments on the rule close August 31, and a comment from a fifteen-bed hospital describing what its 340B book actually funds will carry weight that a trade association letter cannot.

I keep returning to that survey number, because of what it took to produce it. For thirty years this argument was conducted between advocates trading averages, and the government did not know, with any precision, what hospitals were paying. Now it does. And then, having finally measured the distribution, it priced off the midpoint, one national rate for both rooms. The number confirms what both sides already understood, that the program generates a large and real margin exactly as designed. What it cannot tell you is where that margin went, which hospital kept the lights on with it and which one built a suburban infusion suite with it. That is not an unknowable fact. It is known with precision in the conference room this piece opened in, by everyone sitting at that table, several times a year.

For anyone moving from the clinical side into a room where these decisions get made, that is the lesson worth carrying out of a drug pricing fight. Institutions answer to the incentive in front of them rather than to the intention behind it, and reading the incentive correctly is the first thing the new chair will ask of you. There will be a therapy on the agenda, a clinical case already made, and a line in the pharmacy column that decides where the patient goes. Those are the two rooms. They are running on the same statute, and they should stop being governed as though they were the same room.

This is the fourth piece in a thread that runs from what happens when surgery stops subsidizing the hospital through who owes the readiness payment and last week’s look at how executive pay gets set. The map that holds all of it lives here.

From the room you can’t see.

Subscribe now

I have spent more than two decades moving between the clinical rooms and the administrative ones, and the compensation committee is among the quietest of the closed rooms and one of the most consequential. It rarely produces a scandal or a raised voice. What it produces is a figure that helps decide how much room a budget leaves for everything not strictly required, on floors the people in the room will never work a shift.

I want to be careful about the argument I am making, because it is easy to hear a different one. I am not arguing that a given number is too high. That is the argument everyone already has, and it goes in circles, because it turns on a judgment about one person in one year that reasonable people will never settle. The argument worth having is about the features of the room itself: the ones that keep the number out of view, and the ones that push it upward regardless of who holds the seat. I made the same distinction writing about the anesthesia subsidy hospitals fight over, where the subsidy is the symptom and the case leaving the building is the disease. The number is a symptom. The architecture is the subject.

Start with how the number gets built, because the mechanism is more telling than the result. The consultant assembles a peer group, a set of supposedly comparable organizations, and the board sets a target within it: pay the executive at the median of that group or somewhere above it. On its face this is prudent and defensible. It is also, when every board does the same at once, a machine for escalation. If most organizations aim to pay at or above their peer median, and pay rarely moves down once set, the median itself has to climb every cycle, because each board that reaches above average lifts the average the next board measures against. Economists borrowed a name for it from Garrison Keillor’s town where all the children are above average: the Lake Wobegon effect. Each board votes for something reasonable. The aggregate climbs anyway.

The peer group is where the quiet discretion lives. Reputable consultants screen for comparability, usually by revenue band, so the choice is not unbounded. But a board inclined to be generous decides where that band is drawn and which organizations sit at its edges, and can lean toward larger, better-paying systems without ever saying so out loud. The percentile target gets all the attention. The composition of the group beneath it does much of the work, and it does that work before anyone in the room votes on anything.

There is a reason nonprofit health systems lean on this method rather than more independent judgment. Federal tax law rewards them for it. Under the intermediate-sanctions rules, a nonprofit board can establish a rebuttable presumption that its executive pay is reasonable if the arrangement is approved by board members without a conflict of interest, the board relies on data about comparable organizations, and it documents that it did so. Set those three conditions beside the room and the safeguard starts to look thin. The conflict-free body is that same handful of finance-background members, and the comparability data is the benchmarking exercise itself. The rule written to keep nonprofit pay reasonable functions, in practice, as an instruction to benchmark. The very safeguard meant to discipline the number institutionalizes the mechanism that ratchets it. I would challenge us to sit with that inversion for a moment, because it is the clearest case I know of a structural feature producing the opposite of what it was built to do.

Congress has noticed more than once. In 2017 it placed a twenty-one percent excise tax on nonprofit pay above a million dollars, a measure that reads as a check on excess. A tax on the level, though, leaves the architecture that sets it untouched, the whole problem restated as tax policy.

The second feature is what the number lets the rest of us see, and what it does not. For a nonprofit system, the figure that eventually reaches the public sits on a Form 990, a tax filing few people outside the field ever open, and it appears only for a handful of the highest-paid people in the organization. Even that figure can understate the total, because incentive plans, deferred compensation, and other legitimate vehicles move real value into years and forms where it is harder to read in any single snapshot. There is a structural version of the same effect. A large system is rarely one organization but a family of them: some nonprofit and filing a 990, others taxable or for-profit affiliates that file no public return. Pay can be spread across that family in ways that are hard to add up, and for the parts that operate for profit there is no 990 at all. None of this is hidden, exactly. The 990s that exist are public and searchable, and the studies I am about to cite were built from them. It is disclosed the way a thing is disclosed when the disclosure is technically complete and practically unread. The opacity is not a conspiracy. It is the byproduct of an arrangement that was never built to make the community it serves a reader of the number.

Set the mechanism aside and look at the result. At twenty-two major nonprofit medical centers, the pay gap between hospital chief executives and registered nurses widened from twenty-three to one in 2005 to forty-four to one in 2015, while inflation-adjusted nurse pay barely moved (Marcus and colleagues, Clinical Orthopaedics and Related Research, 2018). A 2024 study in PLOS One found that most of the growth in nonprofit chief-executive pay tracks the size of the organization a leader runs more closely than the quality of the care it delivers, and it tied that growth directly to hospital consolidation. That second finding matters, because it means the incentive rewards getting bigger more reliably than getting better, and getting bigger is what the last decade of mergers and acquisitions delivered. A state-level analysis put it in human terms: a North Carolina report found the 2019 pay of eleven nonprofit hospital chief executives equal to the combined salaries of 572 registered nurses. Three numbers, and the last one is the one I cannot unsee.

Here is the objection I take most seriously, because I have watched the work up close and know it is real. Running a multibillion-dollar health system is genuinely hard. The people who do it answer for outcomes across dozens of facilities, they carry a financial weight that can sink an organization and everyone who depends on it, and they are recruited from a small pool by boards competing for the same few names. The leaders I am describing seldom touch a bedside, but they set many of the conditions every clinical team works under, and setting those conditions well is skilled, demanding, consequential work. So is the work on the floor. The nurse who catches a deteriorating patient two hours before the numbers would have, the hospitalist holding twenty admissions in her head at once, the tech who notices the thing on the monitor the protocol missed, each carries a weight measured one life at a time, and it is every bit as real as the enterprise kind. I am not arguing these leaders deserve little, or that the seat should be paid like the bedside. The market for that talent is real, and pretending otherwise would be its own kind of dishonesty.

That objection, though, defends the level of the pay. It does not defend the architecture. A person can be worth a great deal and the process that sets their number can still be a ratchet the community never voted for and rarely reads. Those are two different claims, and the room tends to answer the second by relitigating the first. The difficulty of the job is true. It is also, most of the time, the change of subject.

There is a tell in that phrase, voted for. A public company answers to shareholders who now hold an advisory say-on-pay vote, a chance to register that a number has run ahead of performance. A nonprofit health system has no such vote. The community underwrites its tax exemption, absorbs the consequences of its budget, and staffs its floors, and it holds no seat and no ballot on the number at all. That absence is not an oversight. It is the design.

I have spent the last few issues on a related question, who owes for the cost of a hospital staying ready to take the hard case at two in the morning. This room is the same problem from the other direction. The readiness a system underfunds and the number it protects are set by the same architecture, one that decides behind a closed door what the institution will carry and leaves the rest to the people who were never in the room.

So I keep coming back to the base number. It will shape a Tuesday-night floor eighteen months from now, and it is settled before the committee meets. The ratification, when it comes, can take less time than working up a single complicated admission. To test any of this from outside, the place to look is narrow and public: the peer group a system chose, which surfaces on its 990, and whether those organizations are truly its peers or a flattering reach upward. The board that sets the number rarely sees the three-in-the-morning version of the hospital it governs, and the hospital at three in the morning rarely learns what the number was or how it was set. Both are features of the same arrangement, and the arrangement is working as designed. That is not a reason for outrage. It is a reason to describe the room as it is, so the people who live with the number can at least see how it was built.

This is the fifth of the seven rooms I have been mapping; the map that holds them all lives here.

From the room you can’t see, the voice you need to hear.

Last week I argued that the number a hospital and its anesthesia group fight over every year, the subsidy, is not the real problem but the visible proxy for one. The real thing we are paying for is readiness, the standing capacity to handle the case that does not fit the outpatient model, and we pay for it now through a subsidy negotiated in the dark rather than a readiness payment named in the open. The most useful replies to that piece pressed on the question I had put off on purpose. Fine, they said: if readiness is the thing to pay for, who owes the payment? That is a fair question, and it is harder than it first appears. This is my attempt at an honest answer.

Start with why the question resists a clean answer. Readiness is close to a public good, and it behaves like insurance: the thing of value is the availability itself, the option the whole region holds on the chance that one of them needs the hospital that kept its doors staffed. The emergency department that stays lit before anyone knows who will need it, the team that can take the two a.m. complication, the obstetrics unit and the trauma bay and the intensive-care beds holding the patients too sick to be anywhere else, all of it is capacity the whole region draws on and only part of the region pays for. The surgery center a few miles away depends on that standby by law and pays for none of it: even now, a center has to keep a written procedure for transferring its emergencies to a local hospital, which means the low-cost site’s backstop on its worst day is formally the hospital next door, at no cost to the center. The healthy patient who went to the surgery center still benefits from that standby the day a bad outcome sends them back. Their plan benefits from it without buying it on the ordinary Tuesday. A community that has never once used its trauma bay is safer for its being there. When a benefit reaches everyone and the bill reaches only some, arguments about who owes get hard, because everyone at the table has a true reason to say it belongs to someone else.

There are four defensible answers to who owes, and each makes a real case. The commercial payer that steered the profitable case away has captured the savings and left the standby behind, so the party that captured the savings is the intuitive place to send the bill. The whole payer pool has a claim on it too, because Medicare, Medicaid, the self-funded employer, and the uninsured patient all lean on the same capacity, and a benefit that broad points toward a broad payment rather than a single check. The state has a claim, because standby is public infrastructure and a state like Maryland already sets hospital rates and funds capacity directly. And the community itself has a claim, because it is the community that needs the capacity to exist and, in the end, the community that loses when it lapses. Each of those is defensible. That is exactly what makes the question uncomfortable.

The answer that satisfies first is the commercial payer that moved the case. It is the party that made the choice and captured the gain, and the logic that the party who benefited should pay is neither radical nor new. The site-of-service difference that side of the ledger keeps is even larger in the commercial market than it is under Medicare, which is one reason a growing number of states have started writing site-neutral and facility-fee rules of their own. If you benefited when the profitable case left, the argument goes, you owe something toward the standby it left behind.

I find that answer attractive, and I think it is incomplete, for three reasons worth stating clearly. The first is double payment. The commercial payer already pays hospital rates that fold standby cost into every case it does buy inside the building, so a separate readiness charge risks paying twice for the same capacity. The second is the free-rider problem. If Medicare, Medicaid, self-funded employers, and uninsured patients all draw on the standby, singling out the one commercial insurer that happened to steer a given case is arbitrary, and a benefit that reaches everyone is the standard argument for broad public financing rather than a single-payer bill. The third is the perverse incentive. Charging a payer for readiness wherever it moves a case taxes the very migration most of us agree is right for the healthy patient, and it would prop up duplicated capacity that an honest accounting might say should consolidate. An answer that punishes the good outcome to fund the necessary one is not the answer.

The useful part is that we have already built a version of each of these answers, which means the real work is choosing among working models rather than inventing one. The narrowest and clearest sits where the pressure hit first. When rural hospitals began closing because volume alone could not sustain them, Congress created the Rural Emergency Hospital, which gives up its inpatient beds in exchange for a fixed monthly facility payment, roughly two hundred ninety-five thousand dollars in 2026 and adjusted each year, paid for keeping emergency and outpatient capacity available on top of what it bills for the care it delivers. That is the community-and-taxpayer answer, made narrow and explicit: a public payment for being ready, named as such. Maryland runs the broader version. For years the state has paid its hospitals a fixed global budget for a population rather than a fee for each case, which funds capacity instead of throughput, and at the start of this year that all-payer approach carried into a federal model that several more states are now adopting. That is the all-payer answer: everyone who draws on the system pays into the standby through the rates they already pay.

We even price standby in small, explicit pieces inside our own walls. The on-call stipend and the trauma-activation fee are readiness payments named for what they buy, and the fixed cost of trauma readiness alone, the coverage a center has to staff before the first patient ever arrives, runs into the millions of dollars a year at a busy center before anyone is billed for a single injury. The clearest evidence that the gap is real is the one place the law mandates readiness and declines to fund it: the federal requirement that hospitals keep an on-call panel available for emergencies arrives with no payment attached, and hospitals bridge it with stipends that rarely cover the cost.

Other industries are less shy about pricing the same thing. Electricity markets pay generators a separate capacity price for the promise to be available on the worst day, apart from the power they sell on an ordinary one, and in its most recent auction that promise cleared at a record price across the largest grid in the country as demand climbed. The principle is old and unremarkable everywhere except the hospital: standby is worth paying for on its own, and the parties that depend on it are the parties that owe.

I want to be careful not to suggest a tidy answer, because I distrust them, and because the record is candid about how hard this is. Pennsylvania put eighteen rural hospitals on all-payer global budgets for exactly this reason, to pay for the capacity a community needed rather than the volume it could no longer generate, and the results so far have been mixed, with margins that did not clearly improve and avoidable use that did not clearly fall. That is not an argument against naming who owes. It is a reminder that naming the payer is the first move rather than the last, and that a readiness payment built carelessly can be captured and padded like any other line by the same executives I have watched profit from a patient’s worst day. The case for building it in daylight is exactly that risk.

If I have to force an answer, and I think the question is worth forcing, it is this. Readiness is a public good, and public goods are paid for by everyone who draws on them, not by the single party that happened to move one case. That points toward the all-payer shape Maryland uses or the public facility payment the Rural Emergency Hospital uses, both of which spread the cost across the people who actually depend on the capacity. The satisfying answer, that the commercial payer who captured the savings should write the check, is the honest second-best, the cleanest stand-in when no all-payer mechanism exists, and it should be used with its flaws admitted rather than hidden. What we should stop doing is the thing we do now, which is to leave the bill on the hospital by default and call it a subsidy. The hospital does not simply swallow that bill, either; it recovers part of it by charging the commercial payers more on everything it still does, so a readiness payment is already being made, opaquely, folded into next year’s negotiated rates instead of named on its own line. We pay for it in the dark because the hospital is the one party in the arrangement that cannot walk away from the promise.

I lead an anesthesia company, so let me be clear, because a careless reading turns this into an argument for my own line item. It is not. My group is inside the same loss the hospital is, and the readiness I am pointing at is the hospital’s whole standby function, most of which sits far from my clinicians. Pricing it honestly, and naming who owes it, would end the annual ritual, repeated now at more than eight in ten hospitals that write some version of that check, in which a group and a hospital argue over a number that was never really about either of them, and would replace a private fight with a public accounting. That is worse for the negotiation, meaning worse for my group’s leverage inside it, and better for the institution, which is the trade I would make.

Here is the part that belongs to anyone who has done the work, whether that is the trauma bay at two in the morning, the clinic that holds the complex patient other settings turn away, or the floor team absorbing a surge of admissions on an ordinary Tuesday afternoon. Standing ready is the whole of that contribution, and it stands on its own without having to be justified upward; the institution is only poorer when it fails to listen to the people who carry it. The finance team can watch the subsidy line climb for years and read it as a cost to be managed between two parties in a room. The clinician who has carried the readiness knows what the line is actually buying, and can say what the ledger cannot: that it is not a courtesy and not a market distortion, but the price of a promise the community is counting on, currently billed to the wrong party because we lack the nerve to ask who really owes it. What each of us can do with that depends on where we sit. At the bedside, it is refusing the language of courtesy where the standby actually lives, and naming the readiness plainly in how the work gets described and defended. For anyone with a seat where the number is set, it is refusing to let the subsidy be argued as last year’s figure plus a percentage between a hospital and a group, and putting the real question on the table instead: who benefits from this capacity, who depends on it, and who therefore owes it, measured against the true cost of keeping the doors open. And it is carrying that question up to the level that can answer it, the system board, the payer at contract renewal, the state that sets the rate, rather than settling it in the annual room where a group and a hospital split a number that was never only theirs.

The healthy patient is still home before dinner, and that is still the right outcome; I would argue for it again tomorrow. The person who needs the hospital at two in the morning still needs someone ready, and someone still has to pay for that readiness whether or not we are honest about who. We can keep leaving the bill on the one party that cannot refuse it and calling that a subsidy, or we can do the harder thing and say the word out loud: who owes. Until we answer it, the standby stays an accident waiting on the night it finally fails, and the case that arrives that night will not care whose line item it was.

Subscribe now

In 2009 I was a couple of years out of residency, just beginning to learn the administrative side of an operating room, and my call nights had a rhythm to them. Somewhere after midnight the room would come to life for a perforated bowel: a patient who had come through the emergency department hours earlier, or arrived by transfer from a smaller hospital that had neither the surgeon nor the team to open an abdomen at that hour. The patient had planned none of it. They were sick and frightened and getting sicker, and between the decision to operate and the incision there was no time, and no process, for anyone to ask whether their insurance contracted with our facility. We operated. The coverage question waited for daylight.

Subscribe now

What I could not have told you then, standing at the head of that bed, is how the price of a night like that got decided. Neither the patient nor anyone else in the room had a hand in the number. And in that same season, though I was too deep in learning my own job to read it as a warning, the machinery that set such numbers was coming apart in public view in New York.

Seventeen years later, somewhere in the files of the federal arbitration system that now decides what out-of-network care is worth, there is a dispute in which an insurer reported, under a methodology federal rules currently permit, that the benchmark price for a high-acuity emergency visit was one cent. Behind a filing like that is a patient like mine: someone having one of the harder nights of their life, cared for by a team they never chose. And the filing has company: by a December analysis of the government’s own dispute files, more than sixty thousand disputes carried a reported benchmark under twenty dollars, and in over twenty thousand of those the number was zero. Whatever else those figures are, they are not the median price of anything.

A number like that reads as a clerical error until you learn its family history. I have needed the better part of two decades to appreciate how faithfully it repeats.

In February 2008, the attorney general of New York opened an investigation into how commercial insurers decided what out-of-network care was worth. At the center of it sat a database operated by Ingenix, a subsidiary of UnitedHealth Group, one of the country’s largest insurers. Most of the industry used that database to establish the “usual and customary” rate, the benchmark that determined how much of an out-of-network bill the insurer covered and how much landed on the patient. The investigation found what the ownership structure predicted: the rates ran low, through faulty data collection, poor pooling, and an absence of audits, and every dollar the benchmark understated was a dollar the insurer did not have to pay. The attorney general’s office was direct about the heart of it: a database presented to the public as independent was not independent at all.

The reckoning came in one January week in 2009. UnitedHealth first agreed with the attorney general to shut the Ingenix database down and put up $50 million toward an independent successor, FAIR Health, governed outside the industry it prices. Days later, it agreed to pay $350 million to settle the class action the database had spawned. The episode produced a lesson so obvious it keeps needing to be restated: whoever controls the benchmark controls the margin. A benchmark is not a neutral fact of nature. It is built by someone, from inputs someone chose, and when the builder profits from a lower number, the number finds its way lower.

Eleven years later, Congress had the chance to apply that lesson, and in one respect it did. The No Surprises Act, passed at the end of 2020, rightly protected patients from balance bills they never chose, and it needed a benchmark to make the rest of its machinery work. Lawmakers rejected the discredited “usual and customary” approach and chose something that sounds far harder to manipulate: the insurer’s own median contracted rate for the same service, in the same specialty, in the same market. That number, the qualifying payment amount, or QPA, now does two jobs. It generally sets what the patient owes in cost-sharing when out-of-network care arrives at an in-network facility, and it anchors the arbitration process, the one I wrote about in June, that decides what the clinician is ultimately paid. The diagnosis was right. The delegation is where it came apart. The statute handed the calculation of that median to the insurers themselves, with an opaque methodology and, as it turned out, very little checking of the math.

The construction rules do the quiet work. The median is anchored to rates in effect in January 2019 and carried forward by an inflation index, so rates negotiated in the seven years since do not reset the base. A plan needs only three contracted rates to form a valid median, which means a thin, carefully chosen panel can stand in for a market. Bonus and incentive dollars are stripped out before the median is taken. And the pool may include contracted rates for services the contracted clinician does not actually furnish. This last one, the ghost rate, does the heaviest lifting, and the arithmetic is worth seeing once in concrete form. If an insurer holds contracts with fifty primary care physicians whose panel agreements carry a fifteen-dollar placeholder line for anesthesia services, and contracts with ten anesthesia groups at negotiated rates around two hundred fifty dollars, the median across all sixty contracts lands on the placeholder. The fifteen dollars is a phantom: none of those fifty physicians administers anesthetics, and the line was not actually paid to anyone. It sets the benchmark anyway.

The size of the resulting gap comes from the payers’ own filings. As I wrote in June, a December study matched the QPAs insurers reported to the federal government against the median in-network rates the same insurers published in their own federally required transparency files, for the same service in the same market. The reported benchmark averaged one-third of the insurers’ own contracted rates, and sat below the insurer’s own published median in roughly two-thirds of disputes. The study’s authors are a provider-aligned coalition, and the transparency files are famously messy, so I hold the decimal points loosely. The direction is harder to dismiss, and the mechanism that was supposed to substitute for the subpoena this time has barely been used: since the system went live in 2022, the federal government has completed a single QPA audit.

Between the two eras sits a middle chapter suggesting the lesson stayed commercially alive while the vocabulary changed. Beginning around 2010, many payers routed out-of-network pricing through MultiPlan, a third party whose output carried the appearance of independence. Consolidated antitrust litigation now alleges the platform facilitated coordinated underpayment, nineteen billion dollars in 2020 alone by the plaintiffs’ estimate, with trial evidence they say shows payers could adjust the output. Those are allegations, disputed and unresolved, and I hold them at that weight. The pattern they describe, though, is the Ingenix pattern with better branding.

The courts have been circling the current version for four years. Twice the agencies tried to make the QPA the default answer, first as a presumption and then as a required starting point, and twice the courts struck the rule down, the Fifth Circuit writing that it placed a thumb on the scale in favor of the insurer-determined number. The live question, whether ghost rates and the incentive-payment exclusion are lawful at all, sits today before the full Fifth Circuit, which vacated a panel ruling that had upheld the methodology and has not yet issued its own. While it deliberates, the 2021 calculation rules remain in force under an enforcement grace period that runs through October 1 of this year. The benchmark anchoring a dispute volume that now runs into the millions is, at this moment, a number the courts have not finished deciding anyone was allowed to build that way.

The strongest objections deserve their full weight. Insurers point out that providers win the large majority of arbitrations, at multiples of the QPA, and read that as proof the process is being gamed. I’d argue the arithmetic points the other way: a benchmark that neutral arbitrators overrule most times they examine it is failing at its one job, and the disputes are only the visible edge, because the far larger volume of claims that do not reach arbitration is priced by the same number with no arbitrator watching. It is also true that some of the dispute volume comes from staffing firms, some private-equity backed and some in my own specialty’s neighborhood, that treated out-of-network billing as a strategy, and that conduct is part of what produced this law. The provider side of this fight does not arrive with clean hands.

I should be careful on two further counts. A three-judge federal panel did read the statute to permit the methodology, ghost rates included, before the full court set that opinion aside, so the legal question is genuinely contested rather than settled. And the empirical picture is less uniform than the headline numbers suggest: a Congressional Research Service analysis of emergency services found the median QPA above the median in-network rate in six states and below it in eight, with methods that differ enough from the December study to keep the debate honest. Based upon what we know at the moment, the fairest statement is that the benchmark runs low in most places it has been checked, and that it has barely been checked. The design critique survives even the most charitable reading, because it does not depend on any particular gap in any particular state. The party with a direct financial interest in a lower number holds the pen that writes it. In 2009 we called that arrangement a scandal. In the current version it is a compliance methodology.

I lead an anesthesia company, and anesthesia sits with emergency medicine and radiology among the specialties most exposed to this number, so I am not a neutral party to it, and I have tried to write this in a way that does not need me to be. This is not only a specialist’s fight: the same benchmark helps set what any patient owes on an out-of-network bill, which is why it belonged to the public long before it belonged to a docket. The comparison that matters is not between what providers want and what insurers pay. It is between what the insurer reports the benchmark to be and what the insurer’s own fee schedules say the market is. In 2009 it took an attorney general with subpoena power to put those two numbers side by side. Today they sit in public files, a download apart, for any clinician or executive willing to run the comparison for their own specialty and their own market. Seventeen years ago that comparison shut a database down, and the lesson was supposed to be that a benchmark cannot belong to the party it prices for. Sometime soon, the full Fifth Circuit will tell us whether that lesson holds as law, and whether the next penny in the files is an error or a price. Tonight, in some hospital, an operating room is coming to life for another patient, and the coverage question is again waiting for daylight. We have settled this before. The only question is whether we meant it.

Subscribe now

That case is also the migration in miniature. For most of my career, the smartest people in healthcare have been working to move care out of the hospital. We pushed procedures into ambulatory surgery centers, visits into outpatient offices, and recovery into the home, and for patients the results have largely been good. Care got cheaper, access got easier, and the setting around a routine procedure grew simpler and less frightening. I have argued for that migration myself, in strategy rooms where the math was plain and the benefit to patients was real.

What we discussed far less, because it was harder to see, is what that migration does to the building we are emptying.

A hospital loses money on most of what a community needs it to do. The emergency department, the behavioral health unit, charity and uncompensated care, obstetrics in a rural county, the residency program that trains the next generation: few of these cover their own costs, and several were never built to. For a generation, the operating room has quietly paid for them. Surgical and procedural services have been the hospital’s engine, generating the margin that funds nearly everything the institution loses money on, and most of the people who work on the surgical floor have little reason to watch the gauges. By one industry estimate, surgical and procedural services generate roughly sixty percent of a hospital’s operating margin. That is the engine I mean.

The engine is losing power at the same moment the organization is leaning on it harder. That is the whole of the problem, and it is worth saying plainly before anyone mistakes the symptom for the disease.

It is fair to note, before the finance reader does, that surgery is not the only quiet engine. In many non-profit systems the 340B drug-pricing program has grown into an offset of real consequence, and that room deserves its own walk-through another week. But the lever is available only to some hospitals, and it is under mounting pressure of its own, so leaning on it buys time rather than a trajectory.

Let me be clear about where I stand, because it shapes how you should read the rest of this. I lead an anesthesia company, and my group is not standing outside this problem pointing at it. We are inside it, losing to the same force the hospital is losing to. When the simpler cases leave for the surgery center, the hospital loses the margin that paid for its emergency department, and my clinicians are left with the harder cases, the longer nights, and a workforce that was already too thin. The subsidy a hospital pays an anesthesia group is the number everyone fixes on, and it is the symptom rather than the disease. I am not writing to argue that anyone should pay anesthesia more. I am writing because the case leaving the building is the event that matters.

Four forces are compressing the surgical margin at once, and each of them is a reasonable response to how someone is paid.

The first is the migration itself. High-margin elective surgery keeps moving to freestanding ambulatory centers because commercial payers prefer the lower-cost setting and because refined laparoscopic and robotic technique keeps expanding what can safely be done there, and Medicare’s push toward site-neutral payment, alongside the steady expansion of what it will pay for in an ambulatory center, is eroding the premium hospitals once earned for doing the same procedure under their own roof. The hospital’s advantage is narrowing by design.

The second is what stays behind. As the straightforward, well-insured cases follow the market out the door, the hospital operating room keeps an older, sicker, more Medicare-weighted population. Researchers studying hospitals that lost volume to ambulatory centers found a five percent rise in case-mix index and a ten percent rise in average length of stay between 2019 and 2023. The cases that remain cost more to perform and pay the institution less.

The third is the cost of the people who make surgery possible. More than eighty-five percent of hospitals now write a check to subsidize their anesthesia groups, and even ambulatory centers have begun to: the share expecting to pay an anesthesia stipend climbed from twenty-eight percent in 2024 to forty-four percent in 2025. This is a story about arithmetic rather than appetite. Medicare’s anesthesia payment fell from $22.27 a unit in 2019 to $20.43 in 2024 while clinician compensation rose by double digits, and national benchmarks now put median anesthesia compensation per unit slightly above median collections per unit. The subsidy exists because the work, paid at today’s rates, has stopped covering its own cost. That is the symptom in its clearest form.

The fourth is demand for that same scarce workforce in more places at once. Anesthesia is increasingly required outside the operating room, in cardiac catheterization labs, endoscopy suites, and interventional radiology, where structural heart procedures and advanced endoscopy have multiplied. By claims-based analyses, anesthesia delivered outside the operating room rose from about twenty-eight percent of all cases in 2010 to forty-three percent in 2023, with more than half projected within the decade. The same shortage that strains operating-room coverage now strains coverage everywhere else the hospital hopes to grow.

Put those forces together and you get a financial story that finance alone fails to capture. The part the margin tables miss is what the migration does to the hospital as a place to work.

When the easy cases leave, they take with them the rhythm that made the schedule survivable. The quick, predictable, daytime procedure that let a team breathe between hard ones is now done across town at a center that closes at five and carries no call. What remains inside the hospital is the heavy, complex, after-hours work, concentrated. The surgery center runs no emergency board at two in the morning, and the outpatient office is dark on the weekend, so the nights and the genuinely sick belong, more than ever, to the people who staff the hospital. The same pressure reaches well past anesthesia: the hospitalist, the intensivist, the palliative physician, and the bedside nurse inherit that concentrated acuity too, tending an inpatient census that has grown sicker on average because the well and the straightforward are now cared for somewhere else. For hospital-based anesthesia, the call burden and the unsocial hours have always been the hardest part of the job, and the migration deepens precisely that burden while a retiring workforce thins the bench that carries it. Roughly fifty-seven percent of practicing anesthesiologists are over fifty-five, and the training pipeline is capped by design rather than by interest: in the 2025 match, more than three thousand applicants competed for fewer than nineteen hundred anesthesiology residency positions. The hospital is asking a shrinking group to absorb a harder schedule, and that is a recruiting and retention problem long before it becomes a budget line.

It would be easier to write this if there were a villain, but there is not one. The commercial payer steering a knee replacement to an ambulatory center is lowering the cost of care, which is what we asked it to do. The health system cannot block the migration without forfeiting the cases entirely. The ambulatory operator captures the margin without inheriting the obligation to keep an emergency department open at three in the morning, which is architecture rather than character. Everyone is behaving rationally inside the incentives they were handed, and the sum of all that rational behavior is a hospital slowly losing the means to fund the services a community cannot do without.

This is why the fight over the subsidy is the wrong fight, or at least the small one. The subsidy is the thermometer. It rises because the case that used to run a margin now runs a loss, and arguing over the number treats the measurement rather than the fever. The disease is the departure of the case and the hollowing of the room it leaves behind. A hospital that negotiates its anesthesia subsidy down by a few points and calls the problem solved has cooled the thermometer and left the trajectory untouched. The question worth the energy in the room is the larger one: what replaces what the surgical margin has been quietly funding, and how does the institution keep its inpatient work survivable enough that people will still choose to do it?

I do not have a tidy answer, and I would be wary of anyone who offered one, because the forces involved are structural and they are converging by design rather than by accident. What I would ask of the leaders who sit where I sit is narrower, and I think harder. See the trajectory early, while there is still room to act, rather than waiting for the subsidy line to force the conversation. Acting early looks unglamorous and specific: re-engineering the inpatient schedule so the complex work that remains is survivable to staff, building coverage for the procedures that have moved outside the operating room deliberately rather than reactively, and pricing the subsidy conversation against the true cost of keeping the doors open rather than against last year’s number. Name it honestly to the board, including the part that implicates our own comfortable assumptions about growth. And stop spending the institution’s scarce attention on the thermometer when the fever is the thing that will take the building down.

We were right to move care closer to the patient. The migration made care cheaper and kinder, and I would argue for it again tomorrow. We were wrong to assume the engine room could keep funding everything else while we emptied it of the work that kept it running. The hospital that comes through this decade will be the one whose leaders saw, early enough to matter, that the case leaving the building was never only a billing event. The finance teams could watch the margin fall for years. What the people in the room and at the bedside could see, and say first, was what it was doing to the work itself.

Subscribe now

He chose none of us. He did not pick the emergency physician who evaluated him, the radiologist who read his scan, the anesthesiologist who carried him through the operation, or the pathologist who confirmed his diagnosis. In most of medicine the choosing is half the relationship: you select your surgeon, you read about the practice, you ask a friend who delivered her babies. The specialties that gather around the sickest and most sudden moments are the exception, and that single fact sits underneath one of the quieter fights in American healthcare.

The No Surprises Act got something important right. It decided that a patient who never chose the out-of-network clinician should not be handed the bill for that accident of scheduling, and that was the correct call. In the same motion, the law took away those clinicians’ ability to bill the patient for the balance and replaced it with a single federal arbitration process, independent dispute resolution, as the only road left to argue that the insurer’s payment was too low. So the surprise bill the patient used to receive became a dispute the clinician now files against the plan. The patient is protected. The argument over what the care was worth did not disappear; it moved to a different room.

Most coverage reads that process as a billing squabble, a story about paperwork and arbitrators and fees. I’d argue it is something larger and simpler: a proxy war over who captures the margin on that asleep patient’s care. And the way to tell who is winning is to stop watching the arbitration and watch the benchmark, the single number the rules let one side calculate.

Earlier this month, on June 4, the Departments of Health and Human Services, Labor, and Treasury finalized the long-awaited rule governing how the dispute process works, and the improvements are real. The administrative fee to bring a dispute fell from $115 to $15. Providers can now batch as many as fifty related claims into a single case. Insurers will have to use standard codes to signal, up front, whether a claim is even eligible for the process. The societies that speak for anesthesiology, emergency medicine, and radiology welcomed the rule, and they were right to. When a single radiology claim is worth a modest sum, a $115 fee made it irrational to challenge a payment everyone knew was too low, because the dispute cost more than it could recover. At $15, the arithmetic changes, and a small practice can afford to show up. That is a genuine step toward a process a community group can actually use, and it deserves to be called what it is.

But a process can be cheaper to enter and still rest on a foundation that decides the outcome before anyone walks in. The new rule does not touch the qualifying payment amount, the QPA, the benchmark the arbitrator leans on when deciding what a service was worth. And the benchmark is the whole game. An analysis from Americans for Fair Health Care, a provider-aligned coalition, compared the reported QPAs against insurers’ own published median in-network rates, so the comparison rests on the insurers’ own numbers rather than the coalition’s. In roughly two-thirds of disputes the reported QPA came in below the insurer’s own median contracted rate for the same service in the same region, averaging about a third of the real rate. A median that sits below the real median sounds like a contradiction until you see how the number is built. Tens of thousands of disputes carried a QPA under twenty dollars. Some carried a QPA of zero. Hold that next to the figure insurers cite most often, that providers win the large majority of disputes, and the win rate stops sounding like abuse and starts sounding like arithmetic. When the benchmark is set at a third of the market, an award at three times the benchmark is a correction, not a windfall.

The mechanism that pushes the benchmark down has a name a careful reader will want: ghost rates, the practice of folding into the median the contracted rates for services that were never actually performed, alongside rates borrowed from adjacent specialties that never did the work. It works the way a salary survey would if you padded it with people who were never paid for jobs they never held: drop in enough zeros and near-zeros, and the median sinks toward them. Whether that practice is lawful is the question now before the full Fifth Circuit. A three-judge panel first let the methodology stand; the full court then agreed to rehear the case, which set that panel decision aside, and it has not yet issued its own ruling. While the court takes its time, the Departments have allowed the existing benchmark methodology to remain in force through this fall. So the plumbing of the dispute got cheaper and clearer in June, and the number the dispute turns on stayed exactly where it was, contested and unresolved. That is not an accident of timing. It is the part of the fight that actually moves the money, and it is the part still unsettled.

Follow the money one step further and the proxy war stops reading as a metaphor. A Health Affairs analysis last fall described a mechanism that, if it operates at any scale, ought to change how we read the entire dispute: many plans, or the third-party vendors they hire, take a percentage of the spread between a provider’s billed charge and what the plan ultimately pays. Billed charges are set by the provider rather than by any market, so the number itself is soft, but the incentive it creates is not: the wider that spread, the larger the plan’s own cut. An out-of-network claim produces the widest spread there is, so the program pays the plan more to push anesthesia, radiology, and emergency medicine out of its network than to keep them in it. Put plainly, the more a plan pays a clinician, the smaller its own internal bonus. Seen that way, network contraction is not always the unfortunate byproduct of hard bargaining. In some cases it is the design, and the dispute that follows looks less like a breakdown than like the system working as intended.

I want to be careful here, because this is the point where the argument is easiest to overstate. The mechanism is documented; the scale is not. We do not yet have clean, specialty-level data on how many out-of-network terminations were deliberate rather than incidental, and an honest case names that gap instead of papering over it. Based on what we do know, though, the direction of the incentive is not in question, and it turns the insurer’s central complaint on its head. A party that is paid to widen the very gap these disputes exist to close is not a bystander to the volume. It is closer to the source of it.

The honest objection, the one a well-prepared opponent leads with and the one I’d challenge us to sit with rather than wave off, is that a small number of private-equity-backed arbitration firms file an outsized share of these disputes. Three filers account for something close to half the volume, and one of them has won at award levels that, on their face, look like a machine built to extract. Insurers point at those firms and ask Congress to treat the entire process as abuse. The conflation is their strongest move, and it deserves a real answer. Two things are true at the same time. A firm winning at nine times the QPA is, before it is anything else, evidence that the QPA is broken, because when the benchmark is a third of market, large multiples are the expected result rather than proof of gaming. And the concentration itself exposes an access problem the new rule only begins to address: the parties who can work this system at scale are the ones who can fund a standing dispute operation. The independent anesthesiologist in a community hospital, the clinician the law was nominally written to protect, was until this month’s fee cut largely priced out of the process built in her name. The point is not that every high-volume filer is virtuous. It is that the volume problem, the benchmark problem, and the network problem all share one author.

There is one argument I will not set aside. Self-insured employers, not insurer shareholders, ultimately pay the awards that come out of this process, and a system that moves large sums from employer health plans to aggregators raises a real distributional question that the corruption of the benchmark does not answer. Both can be wrong at once. A piece written honestly from the provider side has to hold that, and I do.

Which brings me back to the man who came through the emergency department on a Tuesday, asleep before he could have weighed in on any of it. The new rule lowered the cost of entering the fight on his behalf, and that matters. It did not make the fight fair, because the number that decides it is still calculated by one of the two parties to it, under a methodology the courts have not finished examining. A cheaper seat at a tilted table is progress. It is not the same thing as a level table, and naming that difference out loud is work any clinician close to it can do, and work the people in leadership exist to carry forward. In practice, that begins with a small, concrete ask: to see how the benchmark was built before the argument turns to what any one award should be. It is the hospitalist who can no longer find an in-network specialist to accept the consult, and the primary care physician left holding what the narrowed network pushes back onto her, who feel these decisions in their own work long before they reach a policy paper. The question worth answering is not whether providers win too often. It is who was allowed to set the number, and why the people closest to the patient had the smallest hand in it.

I have done both versions. I have also watched, in colleagues I admire and in myself, the morning when the ten-minute version quietly and insidiously disappears and only the four-minute one is left. The questions still get asked. The evaluation still gets done. The hands are as good as they ever were. What goes missing is the part where the patient stops being the next case, and the unsettling thing about its absence is how reasonable it feels from the inside. You are tired in a way that sleep does not fix. You have been asked, too many times, to move faster than the work deserves. Faster than the patient in front of you deserves. So the caring is the thing that burns off first, because it is the most expensive thing to keep spending.

That loss has a clinical name, and naming it correctly is the whole point of this piece. Christina Maslach’s inventory, the instrument most of medicine uses to measure burnout, breaks it into three parts: emotional exhaustion, a diminished sense of accomplishment, and depersonalization. The first two describe how the clinician feels: tired and insignificant. Depersonalization is different, because it describes what happens to the people on the other side of the clinician. It is the cynical, impersonal distance that clinical training spends years trying to prevent, and it is the part of burnout that lands most directly at the bedside. You can see it anywhere clinicians work: the clinic visit that ends a question early, the hospital room visit that no longer pauses, the hard consult delivered without the silence the news deserves. An exhausted clinician may still be trying. A depersonalized one has quietly stopped expecting the encounter to matter, and the patient can feel that even when they cannot label it.

The distance is not only a loss of warmth. It travels with measurable harm. A meta-analysis pooling thirteen studies and more than twenty thousand physicians found burnout associated with roughly a threefold increase in the odds of a self-reported major medical error, with depersonalization contributing independently rather than only riding along on exhaustion. And the burden falls across the whole team, not one credential at one end of the hallway. Burnout among certified registered nurse anesthetists, nurses, and advanced practice providers all runs at or above the physician rate in recent national surveys; the instruments and the survey years differ, so those numbers are best read as separate readings rather than a clean ranking, but the direction holds across every credential on the team. My own specialty felt a particular version of it: the share of anesthesiologists reporting workplace staffing shortages more than doubled in two years, from about a third in 2020 to nearly four in five by 2022.

Here is the finding that should change how a leader thinks about all of it. Depersonalization is contagious. A study of intensive-care nurses found that the burnout of the people around you, and specifically their detachment, predicted your own better than the organizational stressors we usually blame. It is a single study, and an association is not proof of transmission, but the finding cuts against the frequent and comfortable assumption that culture flows only from the top. Cynicism turns out to be as catching as exhaustion and considerably harder to see. One worn-down clinician who has stopped expecting the work to matter does not stay one clinician. The posture moves down a unit the way a mood moves through a house, and a culture forms around it: clock in, get through the list, sign out, protect yourself. This is the part the wellness brochure cannot reach, because it was an organizational problem from the start.

The name that has attached to that culture is the shift-worker mentality, and it deserves to be handled with some care, because the phrase carries a sneer it has not earned. It entered medicine two decades ago as a worry about resident duty-hour limits, the concern that capping the hours would produce trainees who watched the clock and felt little ownership of their patients. I am borrowing the term for something those original papers did not quite describe: the experienced clinician, years past training, who has narrowed the job down to its hours on purpose. Said that way, it sounds like a character flaw. It is closer to arithmetic. When the conditions of the work repeatedly ask you to invest more of yourself than the conditions will protect, reducing the investment is a rational decision and not a moral one. It is a very special form of self-protection.

And the conditions that wear a person down are not only the large clinical compromises we name most often. They are the small subtractions of control that pile up underneath them: the clinic or OR start time you cannot push back an hour to take a child to school, the shift you cannot trade, the call you cannot give away. Your own schedule has become a thing you request rather than arrange. Lose enough authority over the shape of your own day, down to the hour, and you learn which parts of yourself the institution means to let you keep, and you stop offering the rest. The clinician who clocks out clean, who has decided the institution will get competence and skill but not the last unguarded part of them, has usually reached that decision for good reasons, and treating it as a failing is both wrong and a guarantee that it deepens.

Which brings up the reframing I find most useful, and the one most likely to make an executive uncomfortable, because it moves the responsibility. In 2018 two physicians, Simon Talbot and Wendy Dean, argued that we have been reaching for the wrong word. Clinicians, they wrote, are not mostly burning out, a phrase that locates the fault inside the worn-out individual. They are suffering moral injury: the particular damage of being required, repeatedly and by people with authority over them, to deliver care they know is worse than the patient deserves. Burnout asks what is wrong with the clinician. Moral injury asks what is being done to them. The distinction is not academic, because it decides where you aim the remedy. If the problem is burnout, you send the clinician to a resilience workshop. If the problem is moral injury, that workshop reads as an insult, because it treats the symptom and leaves the wound exactly where it was.

I want to be fair to the other side of this. Personal resilience is real, the clinicians who guard their sleep and their relationships and their few quiet hours genuinely fare better, and a leader who tells people none of that matters is lying to them. The moral-injury frame is not a permission slip that absolves each of us of any responsibility for our own well-being. But as the primary institutional answer, wellness programming has been studied enough now to be honest about it: the reviews consistently find that organizational changes outperform individual ones, and that resilience training offered in place of fixing the conditions is, at best, a comfortable way to be seen doing something. Talbot put it more precisely than I can, suggesting that burnout is often the end stage of a moral injury that went unaddressed.

So how much can the person in the executive seat actually change, the clinician who crossed into administration and now signs the productivity targets, set against the colleagues I respect who weighed the same move and chose to stay at the bedside on purpose and keep their hands on the work? More than the executive usually admits, though the reach is more indirect than the title implies. Tait Shanafelt’s group at Mayo found that each one-point gain in a supervisor’s leadership score was associated with a three percent drop in the odds of burnout among the people who reported to them, and that at the work-group level, half of the variation in satisfaction traced back to the behavior of the immediate leader. Half. That finding is about the front-line leader one rung up, the charge nurse or the medical director, not the corner office. Which means the executive’s real lever is rarely direct: it is whether those front-line leaders are chosen, trained, and shielded well enough to lead that way. And a one-point gain is not charisma. It is the leader who holds a real debrief after a hard case instead of moving straight to the next one, who carries an unreasonable target upward rather than passing it down, who still learns the names.

That finding cuts both ways, which is the part worth sitting with. The physician leader who enforces a number she knows is unreasonable, who reframes a clinical objection as an operational complaint, who models the very detachment we have been describing, is not a bystander to the spread. She is a carrier. The same seat, used differently, to take real administrative weight off the people doing the work, to say plainly and clearly that what they are carrying is injury and not weakness, to absorb a budget miss rather than pass the pressure down to the bedside, is one of the few real buffers the system has. The leader in that seat is either a carrier of the detachment or a buffer against it, and the people on the team can always tell which.

This is where the personal becomes a community problem, and that turn is the part the wellness conversation leaves out entirely. A clinician who has gone quiet on the inside often leaves for real before long, and the leaving is not evenly distributed. More than a hundred thousand nurses left the workforce across two years, and something close to four in ten of those who remain say they intend to within five. In a city, a single departure is absorbed. In a rural county, where most of the map is already medically underserved and the physicians are older than the ones available to replace them, one surgeon’s resignation can end surgical access for an entire region. The detachment that began as a tired clinician’s rational self-protection, the fault of the conditions and not the clinician, ends several steps later as a town that has to drive two hours to deliver a baby. That is the community cost, and it is the reason this is not a soft subject.

I keep coming back to the four-minute interview and the ten-minute one. The difference between them is the whole thing. It is where trust is built, where the catchable error gets caught, where a frightened person is steadied, where a young clinician learns that the encounter is the work rather than the obstacle to it. When the caring burns off, that difference is the first thing to go and close to the last thing anyone thinks to measure. We have spent years asking clinicians to be more resilient about losing it. The more honest question, and the one that belongs to anyone with the authority to change the conditions, wherever they sit, is what we are doing to the ones that made the ten-minute version feel like a luxury in the first place.

The economics of how those conditions came to be is its own subject, and the next thing I want to write about here. But the human version comes first, because the human version is what a community actually loses when its clinicians go quiet: not a line on a turnover report, but the unhurried, expensive, irreplaceable minute in which a clinician decides to let a stranger matter.

Past the Door publishes free pieces every Sunday. If this one named something you have felt, forwarding it to a colleague carrying the same weight is the best endorsement.

Subscribe now

I am David Wild. I have spent more than two decades moving between two kinds of rooms: the clinical ones, where I still practice anesthesiology a few shifts a month, and the administrative ones, where the conditions for that clinical work get set, the boardroom, the credentialing committee, the contracting table. Most clinicians only ever stand in one kind. Past the Door is my attempt to describe the other ones plainly, and to trace the line from each of them to the bedside, where the consequences land.

If you read one thing first, read the map.

Download the one-page field guide (PDF)

The seven rooms you cannot see is the anchor of everything here. It names the seven closed rooms where healthcare’s decisions actually get made, and gives each one a line. The image above is the keepable version, a single page you can save or send to a colleague. The full piece, with the sourcing, is the pillar it comes from.

Where to begin reading

The map orients; the room pieces go inside. A few places to start, depending on what brought you here.

• For the origin, start with the inaugural, The rooms you can’t see. It is the three-in-the-morning version of why I write this.

• For a room in depth, start with credentialing, the first one mapped fully. What You’re Actually Asking For is the applicant’s side; Inside the Credentialing Committee is the room itself.

• For the leadership thread, What Clinicians Get Wrong Moving to Administration, written with Tracy Young, is on the translator role and the identity cost of the move, and The Coach Who Became a Mentor sits beside it.

• For why any of this matters to me, After the Transplant is the most personal thing here.

The rest of the rooms, contracting, the executive office, peer review, compensation, succession, and the deal room, each get their own piece in the weeks ahead. Subscribing is how you get them as they land.

One ask, and it is a real one. Reply to the welcome note, or leave a comment below, and tell me which room you most want to understand. I read every response, and it shapes what I write next.

Subscribe now

From the room you can’t see, the voice you need to hear.

Mike Rona walked in, looked at the board for a moment, and said, “That’s horse shit.”

He was right, and the memory is worth sharing because of the specific way he was right. The diagram was accurate on its own terms. Every arrow was defensible. It was also wrong, because I had built it without the larger picture in the room: without the people whose work it described, without the parts of the system I could not see from where I stood. All that color was the most rigorous possible version of a small view. He did not hand me the answer. He named the thing I could not see because I was too close to my own analysis. That is a special kind of help, and it has a name.

There is a real difference between a mentor and a coach, and it is not a matter of vocabulary. The cleanest version I know comes from Seehusen and his colleagues, writing in Family Medicine: a mentor talks with you, a coach talks to you. A mentor lends you experience. They have walked your terrain, and they tell you what they learned walking it. A coach does something else entirely. A coach does not need to have walked your terrain at all. Their work is to see your walk clearly, to ask the question you cannot ask yourself, and to hold up the part of your own thinking you have stopped examining.

The distinction tracks a change that every clinician who moves into leadership eventually meets. Early on, you lead because you know more than anyone in the room, and developing other people looks like giving them good advice. Later, if you are willing, leading stops being about what you know and starts being about who you are, and developing other people stops being advice and becomes the harder work of asking rather than telling. Mentoring can transmit experience. Only coaching can change an identity. One reason so many leadership programs disappoint is that they teach skills without touching the identity underneath, and a skill laid over an unchanged identity does not hold.

Physicians are especially prone to the trap. Clinical training builds an expert identity so deep it becomes the water we swim in, and setting it down long enough to grow a second one runs against everything the training rewarded. That is not a failure of the accomplished clinician; it is the cost of how good the training is at making us who we are. I felt it as much as anyone. An anesthesiologist’s whole craft is control and vigilance, and I gave up neither easily.

One thing before going on, because the distinction belongs to everyone and not only to the people climbing toward a title. Some of the best clinicians I know were offered the administrative seat and turned it down on purpose, and they were right to. The coach who helps a veteran nurse see her own teaching more clearly, the mentor who steadies a physician through the hardest stretch of a bedside career, is doing the same work to the same end, with no crossing required. This is not an argument that the rooms upstairs are where the better work happens. It is an argument about how people grow, wherever they have chosen to stand.

Here is where it goes wrong in practice. Medicine is generous with mentoring and stingy with everything else. We pair the young clinician with a senior one, we hand out advice, and we call the development done. What we produce is a generation of leaders who are well-advised and under-coached, fluent in what they already knew and unchanged in how they lead. They have been told a great deal and asked very little.

When I say a coach does not need to know your clinical world, the objection comes fast, and it deserves to be reckoned with. The strongest form is not “I don’t need help.” It is that domain expertise is load-bearing, that someone who has never run an operating room, never carried the liability, never lost the patient cannot tell the universal leadership challenge apart from the one specific to your world. That argument is real, and it is correct about mentoring. You do want a mentor who has walked your terrain.

It is not correct about coaching, and the cleanest proof was written by a surgeon. Atul Gawande, at the height of his career and with his complication rates plateaued, hired a retired surgeon to watch him operate and tell him what he saw. The coach held no expertise in Gawande’s subspecialty. After one twenty-minute conversation, Gawande wrote that it gave him “more to consider and work on than I’d had in the past five years,” and he credited the coaching with the gains that followed. The coach could not have done the operation. He could see the operation. That is the entire distinction, demonstrated by a surgeon at the top of his field. You need a mentor who has walked your terrain and a coach who can see your walk clearly. Confusing the two is what produces the reflexive “I don’t need that.”

What made Mike Rona rare is that he was both, and he knew which one I needed in a given moment. He came into my world as a coach: a formal engagement, external, built entirely on questions. Over the years the relationship outgrew its own category. He began to bring his own arc to bear on mine. He had run Virginia Mason, the health system best known for bringing the Toyota Production System into American medicine, and he had seen the same crossing from the clinical world into the executive one that I was trying to make. The coach became a mentor without ever ceasing to be a coach, and he changed the direction of my career more than once. He was the one who taught me that a leader is given only a handful of moments to stand up and beat a shoe on the table, and that the gesture works precisely because it is rare enough to silence the room, and because you spend it only on the values you will not compromise. The next time such a moment arrived, I knew it for what it was, and I stood. Most people give you one or the other; the rare ones give you both, and can tell, in the moment, which the situation calls for. There is a third role past these two, the sponsor, who advocates for you in the room you are not in, but that is its own piece.

Which raises the question every leader eventually answers, on purpose or by default: what do you owe the people coming up behind you? Liz Wiseman’s work on multipliers and diminishers found that the most damaging diminishers are rarely the tyrants. They are the brilliant, well-meaning leaders who step in too soon, who take the problem back because they can solve it faster, who fill the room so completely that the people in it stop growing. The senior clinician who is too expert to make space is diminishing the people around him and would be the last to believe it. Declining the developmental work does not shrink a leader’s influence. It makes it unconscious and undirected.

So I try to do it on purpose. I convene a forum of our clinical leaders that is, by design, a coaching room: a standing space where the people carrying clinical leadership across our sites bring the problems they are actually carrying, and we work them together instead of my handing down answers.

Consider one of the most common things a clinical leader walks in with: an unexpected change in the leadership above them. The administrator they reported to, the one who knew their program and its history, is gone, and the person stepping into that seat is, for now, a stranger. It is a destabilizing thing to absorb, and it happens all the time. The instinct is to bring it to me for the answer. The more useful move is to put it in front of the room, where someone has almost always navigated the same change and can ask the questions the leader is too rattled to ask themselves: what does the new leader actually need from you in the first ninety days, what in your program is now yours to protect, what reads as loyalty to the old regime that you can no longer afford. That is coaching, and it belongs to the room. Afterward, often, there is a quieter conversation in a hallway or on a call, where what the person needs is no longer a question but the steadying weight of someone who has stood in exactly that spot. That is mentoring, and it belongs to one person who has walked the terrain.

I built the forum in part because of Mike Rona. He gave one version of that to me across a table; the forum is my attempt to build a room that does it for many at once. I have said in rooms like it that we know we have succeeded when the people we develop are ready to put us out of a job, and I mean it, even on the days it costs me something to mean it.

Writing alongside Tracy Young a few weeks ago, I said that the leaders who make these transitions possible are the ones who surround themselves with people who are better, brighter, and carry more potential than they do, and then do not stop there but relentlessly develop the crap out of them. I believe it more the longer I do this work. Mike Rona ran a major health system, and then gave the next chapter of his career to developing clinician-executives one whiteboard at a time. That is what the obligation looks like when a person takes it seriously. He could have told me the answer that afternoon. Instead he told me my beautiful diagram was horse shit, and waited for me to see why.

Past the Door publishes free pieces every Sunday. If this one was useful, forwarding it to a colleague who is working through any of this is the best endorsement.

Subscribe now

Twenty-six pages of paper, bound with a binder clip — that was my first privilege application, near the end of residency. Each page had blanks, dozens of them, and some asked about things I had never had reason to think about before: malpractice history. Prior privilege restrictions. Conditions that might affect my ability to practice. I filled in what I could, submitted the packet, and waited for a letter. What I understood about the room where the decision would be made was essentially nothing.

The packet runs longer now — mostly electronic, which makes it more navigable but no less foreign on first encounter. What has not changed is the opacity: you submit, you wait, a letter arrives.

Most clinicians who pass through the process do so from the applicant side only — and a long, serious clinical career can be built entirely from that vantage point. I have sat on both sides of that table. This piece is about what the second side looks like.

Fifteen years after that first application, I sat in the room where those packets are reviewed, vetted, and occasionally debated in ways the applicant will never learn about. What the applicant side had not prepared me for — and what it never quite prepares the clinician who eventually crosses that table — is how often the tension in the room is not about qualifications. Every month there is at least one scenario where a facility’s coverage need, a new service line, or a rushed application sits directly across the table from a file that is not clean. The space between what the institution needs and what is in that file can draw tight enough that a slow exhale from somewhere at the table reverberates like a plucked string.

There is a distinction that every credentialing packet papers over, and that most clinicians never encounter until they are in the room making the decision rather than waiting for it. Credentials and privileges are not the same thing.

Credentials confirm what you are. Board-certified. Licensed. Trained. The background verification that establishes you as a qualified practitioner in your field.

Privileges grant what you may do at a facility. Specific procedures. Specific patient populations. Specific settings within this institution. The authority to perform a right hepatectomy, place an arterial line, or admit patients is not conferred by your certificate. It is conferred by this committee, at this institution, in this meeting.

The committee can credential you and decline your privilege request. It can grant privileges for some procedures and withhold them for others — not because you are unqualified by training, but because the institution does not need you doing them, because the service line structure does not accommodate them, or because the complications they generate exceed what the institution can currently support. The privilege, unlike the credential, is the institution’s act. It can be withheld, restricted, or revoked for reasons your residency or training program never taught you to anticipate.

Clinicians applying for privileges typically arrive assuming the committee is reviewing their training. What the committee is actually reviewing is considerably more complicated. That review looks backward — case logs, incident history, a prior institution’s adverse action record — and forward: coverage needs, service line strategy, an institutional plan the applicant has never seen and was not required to consult.

The formal mandate of the credentialing committee is the verification of qualifications and assurance of clinical competence: the mechanism through which the institution protects the patients it serves. Every piece of documentation, every attestation, every primary source verification requirement that flows from TJC Medical Staff standards is oriented toward a single claim: the institution will only grant clinical authority to practitioners whose qualifications have been verified and whose competence is reasonably assured. This is a protection for the community served, and one that by design is managed by the medical staff itself.

That mandate is real. The National Practitioner Data Bank query, mandatory for every initial credentialing and every two-year recredentialing cycle, surfaces adverse actions, malpractice payments, and privilege restrictions at prior institutions. References are contacted in most institutions, and they often matter more than they appear to: a hedge from a reference of the applicant’s choosing is reason to look harder; an outright negative from that same reference is a major red flag. Peer review records from within the institution, where they exist, are available to the committee. Records from prior institutions are rarely available in practice. Protection statutes prevent compelled disclosure, and voluntary disclosure is inconsistent. The focused professional practice evaluation period (FPPE) that follows most initial privilege grants is a structured mechanism to verify that the granted authority is being exercised as expected.

When the process works as designed, it is an imperfect but genuine instrument for patient protection.

What the formal mandate does not capture is everything else the committee manages simultaneously.

The institution needs overnight call coverage in the cardiac procedural lab. A structural heart program has been in development for eighteen months, and the committee is reviewing a privilege request from the interventional cardiologist expected to anchor it. The service line economics behind that program are not before the committee. The coverage gap it fills is not on the agenda. The relationship between that privilege grant and the institution’s three-year strategic plan is not part of the formal record.

None of that is improper. Institutions have clinical needs. Privilege decisions that serve both quality and coverage objectives are not compromised decisions — they are how the process is supposed to work when it works. The problem is not that coverage needs influence privilege decisions. The problem is that clinicians who encounter this process as applicants have no window into it, and clinicians who cross to the other side of the table for the first time are often surprised by how much organizational intelligence the room contains that the formal mandate never names.

In the rooms I have sat in, the political overlay is visible before the quality discussion begins, even when it goes unnamed.

Some of it is overt. Two competing cardiology practices on the same medical staff is not unusual, and when an application comes before the committee from a cardiologist who would practice in that same market, the political pressure rarely arrives as stated opposition. It arrives as calibrated scrutiny: volume thresholds that no one examined closely for the previous three applications, FPPE parameters that run longer than the standard, pointed questions about outcomes at the prior institution. Committee members with referral relationships to the established groups may not even recognize the degree to which those relationships are shaping their reading of the file. A well-run committee can name this dynamic when it sees it, precisely because it is tied to a recognizable interest and operates in visible enough territory to be interrogated. The distinguishing question is whether the threshold being applied was already in place, or materialized with this application.

The more consequential version involves existing privileges rather than new applications. A neurosurgeon or orthopedic surgeon is on active staff with an unrestricted privilege set — which means, in many institutions, that the privilege form carries no age limit. When a pediatric patient comes through the emergency department with a problem that falls within that specialty, the clinician can be called. Many have not provided meaningful pediatric care since residency or fellowship.

The request that comes before the committee is not for expanded privileges. It is for restriction. The surgeon wants explicit age limits placed on the privilege form — not to gain anything, but because the next call is coming and they do not want to be in that position. The initial reaction around the table is often sympathetic. The argument is reasonable on its face: a clinician who is not current in pediatric care should not be providing pediatric care.

Then someone asks the question that changes the room: what happens when a pediatric patient presents with something that cannot wait — an intracranial hemorrhage or a vascular injury — and the privilege set the committee just amended specifically excludes children? A restriction that protects the clinician from an uncomfortable position creates a care gap that, in a community hospital without a pediatric subspecialty service, could cost a life. That is not hyperbole. I have watched an adult neurosurgeon take a toddler to the operating room within minutes of arrival to the ED for a hematoma evacuation that could not wait for transfer, because a fall from a shopping cart had produced a hemorrhage that was going to kill that child without immediate intervention.

Both paths available to the committee are uncomfortable. Neither is wrong. The committee’s job is to make the choice it can defend against both the clinician’s reasonable concern and the patient’s unanticipated need.

In many committee cultures, the department chair whose support for an application signals acceptability to the rest of the committee carries weight that the written references do not. The committee member who trained at the same institution as the applicant may read the malpractice history differently than the member who did not. The service line leader who has been waiting three years for this privilege grant will move through the FPPE requirements differently than the one whose existing coverage relationships are threatened by the new applicant.

These dynamics do not make the process corrupt. They highlight its humanity. People read the same application through the lens of their own institutional position, their own professional relationships, and their own reading of what the organization needs. The committee’s job is to produce a quality-grounded decision in the presence of those dynamics, not in their absence.

The medical staff leader who understands this is not more cynical about the process. That physician is more useful to it — more able to see when a quality concern is genuine and when it is a quality-framed version of a different concern, and to recognize which situation requires a harder conversation than the room is currently having. In the pediatric coverage example, the harder conversation is not approval or denial. It is whether the privilege can be structured — through a defined scope, or a clear escalation pathway — in a way that acknowledges the gap honestly and builds the protection into the approval itself.

Peer review protection is what most physician executives encounter first and understand last.

When the committee gets a difficult decision wrong — when political pressure overrides a genuine quality concern, or when a legitimate quality concern is being borrowed to cover something else — there is very little external check. The protection that ensures it stays that way is not incidental to the process. It is built into it.

The protection exists for legitimate reasons. Candid clinical review requires confidentiality. If the committee’s deliberations about a privilege concern were fully discoverable, the risk management calculus would suppress exactly the honest discussion the protection is designed to enable. In most states, the deliberations of a credentialing committee, and the documents produced in peer review proceedings that come to the committee for review, are shielded from discovery in civil litigation for precisely this reason. The process producing the most consequential decisions about a clinician’s right to practice is also, by design, one of the least externally transparent processes in institutional governance. When the committee gets it right, that confidentiality serves everyone. When it gets it wrong, the primary accountability is internal. External mechanisms — Joint Commission reviews, state medical board proceedings, and mandatory federal adverse action reporting — can reach the same questions from a different angle, but they operate at a distance and rarely intervene in the committee’s deliberative process itself.

The physician executive who recognizes this asymmetry is better positioned to ask the harder question — not “is this decision defensible?” but “is the quality concern doing the work, or is it being borrowed for a different purpose?”

For the clinician still on the applicant side of this process — which, for many, is the only side they will occupy — the preceding sections are useful context. For the one moving toward the governance seat, they are the starting frame.

What this means for the physician executive is specific. The culture of the committee is largely the committee’s own responsibility to build and maintain, and within the committee, that responsibility sits most heavily with the senior clinical executive in the governance structure: the CMO, Chief of Staff, or VP Medical Affairs, depending on how the institution has organized that authority. That executive is the clinical voice that shapes what questions get asked, how the room holds the discomfort of a file that is not clean, and whether quality remains the actual driver when a difficult decision is on the table. The physician executive who is not in that seat needs to understand what that culture has already built before they can contribute to it — or challenge it. The question of whether quality is the actual driver of a privilege restriction, or whether something else is operating under that label, can only be asked honestly inside the room. It requires institutional credibility and interpersonal directness. And it requires a clear answer to whose interest the process is meant to serve.

The answer is the patient.

The obligations described here belong to the medical staff leader specifically, because the committee room is, structurally, a physician’s room.

What the physician executive owes the credentialing process is not complexity for its own sake. It is two things, held together, that are in tension often enough to deserve naming.

The first is genuine quality protection. When the NPDB query surfaces something significant, the committee’s job is to take it seriously — not to find a path through it because the coverage need is real or the department chair is enthusiastic. When a colleague’s FPPE reveals a pattern, the committee’s job is to address it before extending the privilege, not after. The threshold is patient safety. Everything else is secondary to it.

The second is organizational honesty about the other things the committee is managing. Coverage needs, service line strategy, departmental relationships — these are legitimate institutional concerns that properly shape how privileges are structured and what proctoring arrangements accompany them. The mistake is not that these concerns exist. The mistake is pretending they are not in the room when everyone present can see that they are, or worse, clothing them in quality language they have not earned.

The physician executive who can hold both of those responsibilities simultaneously is doing something that neither a credentialing committee operating as a purely administrative function nor a medical staff organized purely around clinical autonomy can do on its own. That physician executive is translating between the institution’s organizational reality and its quality obligation, in the specific room where those two things have to coexist. The same logic that produced a structured privilege scope in the pediatric example applies to every table conversation where the quality and the organizational concerns are both real.

The clinician who goes through credentialing as an applicant learns that the process has rules. The physician leader who sits on the committee learns that the process has a culture, and that the culture — not the rules — is what determines whether the process actually does what it claims to do.

Building that culture is not a credentials task. It is not a compliance task. It is the exercise of the specific authority the physician executive carries into a room where the institution is making decisions about clinical practice — decisions that reach forward into every patient encounter involving every clinician the committee approves.

That is the work the training did not name. Being clear-eyed about what it requires is where it starts.

Somewhere, right now, a clinician is filling in those blanks and waiting for a letter. What they know about the room where the decision will be made is essentially nothing.

Past the Door publishes free pieces every Sunday and paid pieces every other Friday. If this one was useful, forwarding it to a colleague navigating the executive transition is the best endorsement.

Subscribe now

Most clinicians develop that rhythm around completion rather than comprehension — which is a defensible trade, until it isn’t. The goal is to get through it accurately, sign it, and get back to clinic. That is a reasonable response to a form that is long, repetitive, and asks for information you have already provided to three other credentialing offices. It is also, quietly, the wrong approach.

The reason comes down to what the form is.

The form is not a record-keeping document. It is a legal instrument. What you sign at the end is not an acknowledgment that you have filled in your training history — it is a request for the institution to grant you specific clinical authority. The distinction matters more than it appears, and it matters most in the section most clinicians complete with the least attention.

The most common behavior, across new and experienced applicants alike, is to check everything on the list that falls within their specialty area. The reasoning is intuitive. More privileges means more coverage. An unrequested privilege is a gap in your practice that might create a problem later. If the form offers a box, and the box is within your specialty, there seems to be no cost to checking it.

There is a cost. It is just not visible at application.

The privilege set you request is what the institution authorizes you to perform. It is also what the committee will compare to your case logs at your next recredentialing cycle. If the privileges you hold say you perform a procedure, and your cases from the prior two years do not support that, that discrepancy lives in your record. At renewal, the committee has both the privilege set you asked for and the cases that do or do not reflect that you used it. A gap between the two requires explanation.

Requesting privileges you do not intend to exercise, or that your practice in the prior cycle does not support, is not a hedge against future gaps. It is a paper record that does not match your actual practice, held by an institution that will look at both.

The second consequence of reading the form carelessly is more immediate: what it says defines what you can be asked to do, now, not at renewal.

Privilege forms carry language. A privilege described as applicable to adult and pediatric patients does not become a pediatric privilege only when you want it to be. At many institutions, the privilege structure and call coverage are explicitly connected — call is a standing obligation for active clinical staff unless the medical executive committee removes that obligation for a particular applicant or department. Where that structure applies, a privilege you hold creates real exposure: if a clinical need arises within that scope, your name is in the system as someone credentialed to provide that care, and the institution’s response to that need may include you before you have had any opportunity to revisit what you signed. Clinicians requesting privileges in a given specialty are thinking about the cases they expect to take. Your scope at that institution is whatever the form says, not whatever you intended when you checked the box.

This is not an argument against requesting broad privileges where they are genuinely warranted. It is an argument for knowing what you are requesting. The form tells you. Reading it is the first step in understanding your actual clinical scope at that institution — not in theory, but on paper, in the institution’s records.

The third issue produces the most risk with the least visibility.

The decision about which privileges to request is inherently a clinical judgment. Clinical judgment cannot be delegated to the person submitting the paperwork.

Physicians and advanced practice providers in group and employed settings frequently have their office complete the application on their behalf. An administrator or coordinator fills in the employment history, tracks down the references, and marks the privilege checklist. The clinician reviews, signs, and returns it.

The administrator filling in that form is making selections about clinical authority. They are not doing this carelessly — they are trying to get the application right, working from whatever guidance they have about what the physician typically does. But they are a non-clinician making a legal request for clinical practice privileges at a specific institution, without the clinical context that would allow them to weigh what those privileges mean or what supporting case logs the physician can produce at renewal.

The clinician who signs without reading the privilege section is trusting that someone else accurately characterized their clinical scope and the evidentiary record behind it. That trust is more often misplaced than reasonable — not because administrators are careless, but because the decision is not theirs to make.

You are not filling out paperwork. You are making a specific, documented request for clinical authority at a specific institution, with a record that will follow you through every renewal cycle.

Of all the steps in the credentialing process, the application is the only one the applicant controls. What follows — the review, the deliberation, the decision — happens in a room the applicant never enters. The proportional attention most clinicians give to the part they own versus the part they don’t is almost exactly backwards.

That is where this series goes next. It publishes free Friday as a preview of what paid posts look like. The paid tier opens June 23.

Past the Door publishes free pieces every Sunday. If this one was useful, forwarding it to a colleague who is working through one of these is the best endorsement.

Subscribe now

A conference room in an office park, mid-afternoon, two teams on opposite sides of a long table. One represents a health system, the other a large insurer. They are negotiating unit prices, the rates the insurer will pay for a list of procedures, and the work is slow and unglamorous, conducted in spreadsheets and redlines. By the end of the day they will agree on a number. The word “nurse” is never said aloud in the room. And yet the number they settle on will decide, eighteen months from now, how many nurses are scheduled on a given floor on a Tuesday night, and how much room the budget leaves for anything that is not strictly required.

The people who will live with that number are not in the room. The nurse on that future Tuesday night is not here. Neither is the patient whose call light she will be slower to answer because the floor is one body short. The decision that shapes their evening is being made, reasonably and in good faith, by people who will never meet them.

This is the first thing to understand about healthcare’s closed rooms. They are not sinister. The decisions made in them are rarely malicious and almost never hidden. They are simply closed to the people whose work and lives are shaped most directly by what happens inside them. The teams at the table, often on both sides, have rarely been in a hospital room except as a patient or a visitor.

There is another kind of room entirely. The operating room at three in the morning. The intensive care unit. The recovery floor. These are rooms about the patient, where the most human parts of medicine happen and where the decisions that matter most to a single person get made in real time, by the people standing over the bed. Most of us can enter one kind of room or the other. Almost no one sees both.

I have spent more than two decades moving between them, the clinical rooms and the administrative ones, and I have come to think of the administrative side as seven rooms. Some readers know these rooms perfectly well and have chosen the bedside on purpose; what follows is not an argument that the rooms are where the better work happens, only that what gets decided inside them reaches the bedside whether or not the bedside ever sees the room. Here is the map.

The contracting room

We have just been in the first room. It is worth staying a moment longer, because it shows the pattern the other six repeat. Two things make it consequential. The first is who is absent: the negotiation has a chair for the system and a chair for the payer, and not one for the nurse, the patient, or the clinician whose Tuesday night the number will shape. The second is time. The negotiation itself is often a series of meetings stretched over weeks or months, where a change made at the end can quietly undo something agreed at the beginning, and the gap between the final decision and its effect runs another twelve to eighteen months. By the time the floor feels the squeeze, almost no one traces it back to a number agreed a year and a half earlier in an office park. The decision and its consequence are severed cleanly enough that the room is rarely held to account for either.

The credentialing committee

The second room decides who is allowed to do the work. The physicians already on the medical staff review the files of the physicians, nurse practitioners, and physician assistants who want to join them, and they hold the authority to say yes or no. It is a necessary function and, done well, a careful one; the rigor is the reason the work carries the trust it does. The friction is that the process is structurally slow, gated by primary-source verification and payer enrollment as much as by the committee’s own calendar, and unforgiving of timing. A fully qualified clinician with a clean file can miss a cycle over an administrative detail that has nothing to do with competence, a license that transferred a few days late, a signature that landed after a cutoff. Each name that does not clear in time is a name that is not at the bedside the following month, and in a market already short of clinicians, the cost of that delay falls on the patients who wait and the colleagues who cover the gap. Most patients never picture this room, and it helps determine who is there to care for them.

The executive office

The third room is where workforce planning meets arithmetic. At some point every system runs into the same wall: there are not enough trained clinicians to fill the roles, and the gap is widening as the population ages.

The story most people hear is that fewer young people want clinical careers. The actual problem is closer to the opposite. The binding constraint is training capacity. The 1997 Balanced Budget Act capped the number of Medicare-funded residency positions at roughly their 1996 level, where they stayed essentially frozen for more than two decades until Congress added the first new slots in 2021 and 2023 (AAMC). The pressure shows in the Match: in 2025, more than 47,000 active applicants competed for roughly 40,000 first-year positions, and about 9,500 of them did not match into one (NRMP). On the nursing side, the American Association of Colleges of Nursing reported that schools turned away more than 65,000 qualified applications in 2022 for lack of faculty, clinical training sites, and budget (AACN). That is a different problem than the one most leaders are solving for, and it has different solutions.

The peer review committee

The fourth room is where the clinical and the administrative meet. When a hard case goes to peer review, a physician’s work is examined by colleagues behind a closed door, and the lessons of that case do not stay with the clinician; they become the standard the whole department is held to afterward. A single difficult airway, reviewed honestly, can change the preoperative checklist every colleague follows the next morning. This is clinical governance at the case level, and it is closed for good reasons, including fairness to the clinician and candor in the discussion. It is consequential precisely because the rest of the department inherits whatever the room concludes. There are other rooms like it, the morbidity and mortality conference, the privileging committee, the quality review group that reviews nursing care and medication errors, and I will write about each in time.

The compensation committee

The fifth room is where senior executive pay gets set, and most of the decision is made before anyone sits down. A consultant builds the number over weeks against a hand-picked peer group and a target percentile, and a compensation committee of a few board members, usually with backgrounds in business or finance, meets to ratify it, often in under an hour. The deliberation stays inside the room. Even what eventually becomes public can understate the total, since incentive structures, deferred compensation plans, and other legitimate vehicles reduce what is reportable in a single year. The figure that does surface, for a nonprofit system, sits on a tax form almost no one reads, and only for a handful of the highest-paid executives.

I am not arguing the nonprofit construct is broken. I am arguing it has features that let compensation outrun the mission’s reach into the community, and that the conversation we are not having is about the features themselves. The numbers we can see point at the tension. At twenty-two major nonprofit medical centers, the wage gap between hospital chief executives and registered nurses rose from 23 to 1 in 2005 to 44 to 1 in 2015, while inflation-adjusted nurse pay barely moved (Marcus et al., Clinical Orthopaedics and Related Research), and research on nonprofit systems has found that most of the growth in chief executive pay tracks the size of the organization a leader runs more closely than the quality of the care it delivers (PLOS One). One state-level analysis went further still: a North Carolina report found the 2019 pay of eleven nonprofit hospital chief executives equal to the salaries of 572 registered nurses (NC State Health Plan).

The succession room

The sixth room decides who comes next. The question of who replaces a chief executive when she retires gets answered long before the rest of the organization knows there is a question, and the way it gets answered tells you what a board actually values. I have said in rooms like this one that we are successful when those we develop put us out of a job. That line tends to cool a room, because most leaders still measure success by how long they hold the seat rather than by who they have ready to take it.

The deal room

The seventh room is where a community hospital becomes a chain asset. Mergers and acquisitions are how a great deal of American healthcare is now organized, and the logic of a given deal is usually sound on its own terms. Often it is more than sound; the capital and the capability a larger partner brings are sometimes the only thing that keeps a struggling hospital’s doors open, and I have changed my own mind over the years about how much good the right partnership can do. What the model on the table almost never prices is the local discretion that lets a hospital do something for its community that would never clear a system-wide spreadsheet, along with the slower effects on the credentialing pipeline and the staffing ratios this map has been tracing. Decision rights move upward and outward, toward the standard and away from the floor, and that trade is real whether or not anyone in the room names it. Those effects show up eighteen months after the signing, in rooms the deal room never has to sit in.

The force that runs through all of them

There is an eighth space I have deliberately left off the numbered list, because it does not behave like the others. The rulemaking process, where a federal or state agency sets a payment rule through notice and comment, acts on several of the seven at once. A change to how procedures are paid for reshapes the contracting room and the deal room together. A change to how training is funded reaches straight into the executive office. Regulation is less a room you enter than a current that runs underneath the others, and it moves the water in all of them.

What this map is for

A word on what this is not, because the discipline matters and is worth saying aloud so a reader can hold me to it. This is not a map for gossip. It does not name and blame. It will not trade on outrage to keep your attention, and it will not critique former colleagues or employers in public, because that work belongs in private conversation. What it will do is describe, plainly and specifically, what happens in the rooms most readers never enter, and trace the line from each of them to the bedside, where the consequences land. I will credit the people whose work I respect by name. I will sit with complexity rather than pretend it away. And when I change my mind about something I have argued for here, I will say so and explain why.

The reason to draw the map at all is that the people in the clinical rooms and the people in the system rooms are, more often than either side admits, working toward the same thing and unable to see each other do it. The family in a surgical waiting room cannot see the contracting room that set the staffing on the floor where their father will recover. The board in the compensation committee rarely sees the three-in-the-morning version of the hospital it governs. Almost no one in American healthcare can stand in all seven of these rooms and the clinical ones too, and the cost of that is a system whose halves keep deciding each other’s conditions without ever meeting.

The number agreed in that office park takes effect long after anyone remembers the meeting. The nurse who is one body short on a Tuesday night will not know why, but she will be the first to feel it, and her floor is where a year-and-a-half-old number finally becomes legible as a real night with a real patient. The people who set the conditions she works under will never see that floor at the hour it is hardest. Most of these rooms close before the consequence arrives, and open again before anyone connects the two. The slow work of this newsletter is to connect the decision to the floor it lands on, so that the people in the rooms and the people at the bedside are at least describing the same system.

From the room you can’t see, the voice you need to hear.

Download the one-page field guide (PDF)

Each of the seven rooms gets its own piece. Subscribe at pastthedoor.com to read them as they publish.

By the time we met, the story many people read earlier this month had already happened. The Thursday that felt like a cold. The Friday night his heart, lungs, kidneys, and liver all began to fail. His wife Jordan, three months pregnant, waiting in the hospital parking lot because pandemic protocols wouldn’t let her inside. A ventilator twenty minutes after he walked through the ER doors. A life-flight. A national transplant waiting list. A heart, two days later, from someone whose name he didn’t know.

I met Tristan after. The version I know is the one who came out the other side.

What I have watched, close up, over the years since we became friends, is what someone does with time they weren’t supposed to have. He has spent it building. Earlier this month, he and his team introduced Transplants.org to the world. I have been an advisor for several years. Here is why I said yes, and why I think it matters.

Tristan’s own account is worth reading in his words before or after this one: Tristan's post on LinkedIn

What I can offer is the clinical read on the speed of it.

In Tristan’s case, multi-organ failure didn’t announce itself. A cold on Thursday. By Friday night, four organ systems in crisis. For anyone who works near a hospital, the sentence that lands hardest is this one: ventilated twenty minutes after walking through the ER doors. That is not slow deterioration. That is a body shutting down faster than most people can imagine, in a window measured in hours, not days.

The other sentence worth pausing on is the one about five years of memory loss as the cost of the oxygen deprivation that came with the organ failure. He woke up alive. He woke up missing five years. The heart was a gift. What accompanied it was not.

That is worth sitting with for a few minutes. What the system counts — the transplant, the discharge, the organ function — is not the same as what the patient carries every day after they leave the hospital.

The transplant system Tristan came back into is exceptional at certain things and genuinely inadequate at others.

What it does well: the acute phase. The allocation and procurement process, the surgical care, the transplant coordinators in the immediate post-operative window. The coordination required to move a viable organ from one person’s chest to another’s in a matter of hours is remarkable. We are, as a system, very good at the part that gets you to discharge.

What comes after discharge is a different matter.

Once a transplant happens, immunosuppression is for life. With very rare exception, that medication is taken every day until the recipient dies — stopping it is how the organ is lost. The medication keeps the new organ alive by suppressing the immune system, which creates a constant balancing act: suppress too little and the body rejects the organ, suppress too much and infection becomes the threat. Over years, that same suppression raises the risk of malignancy — post-transplant lymphoproliferative disease and skin cancers among the more serious late concerns. Managing that balance across an ordinary life that includes travel, illness, aging, other medications, and stress is lifelong work. Much of that work, the patient and their family figure out largely on their own.

The questions that come up seem simple at first. Is this symptom rejection, or something else? Who do I call at 11 p.m.? What does the new doctor who didn’t do my transplant need to know? The transplant center is built for the acute phase. Over time, for many patients, it becomes harder to reach, and the answers get harder to find.

Transplants.org was built for what comes after.

It is a nonprofit focused on the full arc of the transplant journey: from first consideration through the listing process, through recovery, and through the decades of lifelong management that follow. In practice, that means resources for the patient navigating immunosuppression in year four, for the family that doesn’t know which doctor to call at midnight, for the primary care physician who took on a transplant patient without ever having trained for it. It is not affiliated with a specific hospital or transplant center. That independence matters. It lets the organization follow the patient rather than the institution.

Medical advisors from Mayo Clinic, Cleveland Clinic, Vanderbilt, UCLA, and Duke. Policy advisors with federal health legislation experience. Oracle and United Therapeutics as organizational supporters from the beginning.

My stake in this is worth naming. I have been an advisor to Transplants.org for several years. Tristan and Jordan are close personal friends. I have no equity in the organization and no financial relationship with it. I am writing this because the mission is right and the team is real, and because I have watched the work closely enough to believe both of those things.

What I bring to the advisory role is a clinical view of what the post-transplant journey looks like from the care side. My specific clinical expertise is in liver transplantation. I have some sense of what patients and families carry out of the hospital when the acute phase is over.

Tristan uses the phrase “bonus time.” It appears in the post he published earlier this month, and I have heard him use it before.

Most people who survive what he survived are grateful. Most go on to live well. A smaller number feel the pull to do something with the life they were given back. Tristan is doing something that most people, even those who feel that pull, do not do: he is building an organization for the next person in that ICU bed.

The question that comes with watching that, at least for me, is not a comfortable one. Why does it take a heart transplant recipient to build this? What does it say about the system that this organization did not already exist?

I have a partial answer. Medicine trains clinicians to deliver care within existing institutions, not to build the ones that don’t yet exist. The knowledge and the instinct to close a gap like this can accumulate over a clinical career. The capacity to act on it — the time, the access to capital, the freedom to move without institutional approval — almost never does. Tristan came back to his life with something unusual: a mission that required no organizational permission to pursue. That is an uncomfortable thing to say about a field that otherwise works hard at developing its people.

What Tristan built sits in that space — outside the institution, accountable only to the patient.

Visit Transplants.org. If you know a patient or a family navigating the transplant journey, send them there. If you are a clinician working in transplant medicine or adjacent to it, follow the work.

I met Tristan after the transplant. What I have watched since is someone doing something uncommon with the time he has. It is worth paying attention to.

Tracy Young is the co-founder and Chief Operating Officer of Essential Anesthesia Management and a practicing CRNA. He has been on every side of the clinical-executive translation question in this organization. We wrote our sections separately and edited each other's. The conversation was worth having in both directions at once.

The first formal feedback I received as a new executive came at a small, round, four-person table in the corner of a very typical executive office. Dark wood furniture, a desk and table both carrying stacks of papers and file folders, the printout of a PowerPoint deck for the upcoming board meeting laid out in front of the CEO and the COO. I had presented to the Executive Team from that deck the day before. I had walked into the meeting expecting we would talk about the substance of what I had presented. We did not, at least not in the way I expected.

The feedback was not about a decision I had made. It was not about the substance of the deck. It wasn’t about my expertise as the physician executive on the team. It was about how I was showing up in the room. The CEO told me, specifically and warmly, that I needed to slow down. That I needed to strip the technical expertise from my lexicon and my presentation style. That the rest of the senior team and the board needed the space and the time to ingest what I was sharing, sit with it, ask questions, and land on a good decision themselves. The COO did not say much, but she did not need to. She was nodding at the right beats, and I could read in the rhythm of her agreement that this was a conversation the two of them had decided was worth having before it got harder to have.

What I remember as clearly as the words themselves is the feeling of the conversation. This was not criticism. This was the first round of honest, direct feedback from someone who had decided, before I walked in, that the incorporation of it was critical to my success and growth as an executive, and that the same incorporation would bring benefits to the organization as a whole. The two were not in tension. They were the same investment, made twice. I had spent the twenty years before that conversation training to be the most prepared person in the room. The CEO was telling me, in the most generous way he knew how, that I had taken a job that called for a different skill set. A different way of showing up.

That conversation has stayed with me for the better part of a decade. Almost every time I have watched a clinician make the move into administration since, I have recognized a version of the same gap. The version I lived was about cadence and language. For someone else, it might be how meetings get run, or how decisions get framed, or how disagreement gets handled. The shape underneath each of these scenarios is the same. Clinical training rewards being the answer. Executive work, especially across a senior team, is about creating and holding the space that makes the answer-finding system work.

I’d argue that this is the single most important reframe a clinician moving into administration has to make, and the one most clinicians moving into administration miss for longer than they should. At the bedside, expertise is the asset. The patient in front of me benefits from the fact that the clinical team around them has read more, trained more, and seen more of this specific clinical scenario than almost anyone they will encounter on the worst day of their life. In the C-suite, expertise is one of fifteen things in the room, and rarely the most important one. The job is to lead a body of work in which I am the second, fifth, or tenth most expert voice about almost any given decision. The Chief Operating Officer knows the operations better than I do. The Chief Financial Officer knows the economics better than I do. The Chief Development Officer knows the pipeline better than I do. My job is to make sure the right clinical reality is in the room, in language the rest of the team can act on, before they make a decision that will live or die at the bedside.

When I have not done that well — and I have not done it well plenty of times — the failure mode is recognizable. I show up too prepared. I anchor the room early. I leave too little oxygen for the operators and finance leaders to bring their own constraints into the picture. The decision the room reaches is technically correct and operationally fragile at the same time. We end up implementing something the front-line clinicians cannot actually execute, and three months later we are doing the work over again from a worse starting place. Slowing down, stripping the lexicon, and making space turns out to be more than a presentation note. It is the actual mechanism by which a senior team makes good decisions together.

Once a clinician learns to stop showing up as the answer, the question that takes its place is a different one. Not “what should we do,” but “what is the room actually missing that I am uniquely positioned to bring.” The honest answer to that, in my experience, is rarely the technical knowledge the team assumed they were getting when they hired the clinician.

The job most clinicians think they are taking and the job they have actually taken are not the same job. Most assume the role is, at its core, the clinical voice in the C-suite. That description is not wrong. It is incomplete. The function of the job is the translator role, and the translator role is the load-bearing wall of the seat.

What I mean specifically is this: if I cannot carry a clinical concern to a non-clinical COO in language she can act on — meaning she understands the operational shape, the financial implication, the workforce signal, and the decision she is being asked to make — I have not done my job, no matter how well I have understood the clinical concern myself. Conversely, if I cannot bring an operational reality back to a clinical lead in language he can act on — meaning he understands why a contract distinction changes how the OR director feels about a six o’clock Friday case, or why a payer mix affects which staffing model is sustainable at his site — I have not done that job either. The clinical voice in the room does not stop at telling the truth about the clinical work. It keeps going, into making the truth usable to people who do not live inside that work day to day.

One of the clearest examples I can recall sat at the intersection of ability to pay and non-emergent but life-saving care. Cancer treatment, transplant work, the kinds of cases where insurance coverage shapes whether a patient has a path forward. For several rounds in that conversation I did not create enough space to hold the real question the organization was sitting on. The clinical team was carrying the moral injury of saying no, or watching the system say no on their behalf, to patients who did not have a financial path to long-term management of their care. The no-margin-no-mission line everyone in the room had already absorbed was real and unmoving. The conversation kept landing in one of those two corners and breaking against it.

The translator move I eventually learned was not to choose a corner. It was to hold the room long enough for the finance team and the clinical team to land somewhere together — a place where the conversation shifted from whether the organization could afford to say yes to how a conditional yes could be structured: what the program could commit to upfront, what the patient could demonstrate over time, and where the clinical and financial risk would sit between those two realities. The lead message to a patient could be options rather than a no, and patient autonomy could carry the weight of the decision. That message did not exist in the room before someone created the space for it. The seat I was in was the seat that was supposed to do that work.

The last one took me the longest to see clearly, and I think it is the one most clinicians moving into administration handle without ever putting language to it. It is the question of what to do with the clinical practice itself. I still pick up a few clinical shifts a month. I do that because the patient interactions ground me, because the teams I work alongside on those days are one of the strongest reminders I have of what we are building EAM around, and because the clinical specifics keep me current in a way that helps me lead the company. Those shifts are additive. They make me better at the executive work, not worse.

I have also watched clinicians in administrative roles hold onto a clinical practice for a different reason. The executive role feels uncomfortable. The clinical role feels familiar. The hours in clinic or in the OR become a way to recover the identity that the new seat is asking them to reshape. That is the protective version of the same arrangement, and it does not announce itself as protective at the time. It looks like commitment. It looks like staying connected to the work. The candid take on it usually requires someone outside the situation to label it, and the person hearing it named almost always pushes back the first time, because the protective version of the practice is doing real psychological work for the clinician holding onto it. What it is doing, specifically, is grieving. Or, in the language I tend to use, holding onto something the move into the executive seat carries a real fear of losing. Standing in the clinical hierarchy, the rhythm of being known by what your hands do, the patients themselves. Those losses are real, and they are not small. The protective version is the version that has not figured out how to live with the loss yet.

I am not arguing that clinicians in executive roles need to give up their practice. I am arguing that clinicians in executive roles need to be honest with themselves about which version they are running. I’m saying out loud that the job requires a certain amount of straddling the fence between the two worlds, but in a way that recognizes and capitalizes on that position. And I am arguing that the leaders who hold the development relationships inside those organizations — the CEOs, the co-founders, the senior executives who have made the transition and remember what it cost them — need to make it safe to have that conversation out loud, so that the protective version can become additive or fall away.

You and I came at this seat from opposite ends of the same problem. You built up through the firm — a clinician who became the operational executive, then a co-founder, then a partner who has been on every side of the clinical-executive translation conversation in this organization. I came in from outside it, after twenty years of clinical practice and fifteen of executive work in large health systems where the seats and the systems looked very different from the one we are running together now. The thing we agree on, before any of the rest, is that clinical training does not prepare a person for what these jobs actually ask. The other thing I have come to believe, watching it from both sides now, is that the transition does not happen alone. The CEO and COO at the table I described in the opening had decided, before I walked in, that the incorporation of their feedback mattered both to my growth and to the organization. The leaders who make these transitions possible are the ones who surround themselves with people who are better and brighter than they are. And then they do not stop there. They name the gap before it becomes a pattern, and they stay in the room after the feedback is given. The longer answer to all of this, and the part I am most curious to read, is the half you are about to write.

— David

---

David,

Reading your half, the phrase that kept coming back to me was your idea that clinicians are trained to become “the answer,” while leadership requires us to create the conditions where the best answers can emerge from the group. I think that is exactly right. And I think it explains why so many exceptional CRNAs, and clinicians more broadly, struggle when they first move into administrative leadership. The skill sets overlap far less than people assume.

My own journey from clinical CRNA to founder, business owner, and senior executive has been a slow evolution over more than 20 years. The honest truth is that the evolution is still happening. Daily.

As CRNAs, we talk about being lifelong learners clinically. We accept that mastery requires continuous development of knowledge, judgment, and technical skill. But many clinicians underestimate what the transition into administrative leadership requires, and that underestimation can make the transition far more difficult than it needs to be.

I think of the Dunning-Kruger curve, where early success can feel like mastery just before the floor falls out. Clinicians have lived this phenomenon during training, during early practice, and during the long arc of mastering a craft. We somehow fail to apply the same humility when moving into leadership. We assume that because we were excellent clinically, leadership will come naturally.

It usually does not.

One of the first things I noticed was the loss of the immediate feedback loop we get in clinical anesthesia. As a CRNA, I was used to making a decision and seeing the physiologic response in seconds or minutes. The work is tangible. The feedback is immediate. There is comfort in that. There is certainty in that. There is identity in that.

Leadership is much messier.

The other early lesson, after starting my own company and growing it, was that my personal ability to perform anesthesia became progressively less important to my success as an executive. That sounds strange to say out loud in a profession where clinical excellence is rightly revered, but it is true. The larger the company grew, the more the job became about building systems, developing people, creating alignment, and helping teams solve problems together. Scale is impossible without that network. No founder can be the answer to every problem and have it work.

The move from clinical CRNA to leader is really a move from personal execution to organizational execution. That transition is uncomfortable for clinicians because we were trained and rewarded for being individually excellent. Leadership rewards patience, communication, emotional control, long-term thinking, the ability to simplify complexity, and the ability to create buy-in instead of being correct.

That journey for me was slow, not linear, and not always graceful. I fought it at times. Then the weight of the role landed in a way I could not push back against, and I understood that leadership was not about having all the answers. It was about helping the organization become capable of finding better answers together.

I have watched incredibly smart CRNAs fail in leadership roles because they believed their clinical expertise alone would carry them. Clinical expertise gets you invited into the room. What determines whether you remain effective is your ability to build trust, align people, and translate complexity into action.

Your point about the translator role resonated with me because it may be the core function of clinicians in healthcare leadership. Clinicians often underestimate how little operational, financial, and organizational context exists outside their lane. Executives sometimes underestimate the realities and constraints of clinical care. Someone has to bridge that gap, and clinicians who learn systems thinking and the broader environment are uniquely positioned to do it.

As a COO, I have often translated in the opposite direction of the examples you described. I understand why a facility administrator is focused on subsidy structure, payer mix, staffing efficiency, or contract language. I understand why a CFO worries about labor expense growth or why operations is trying to standardize workflows. But if those realities reach clinicians without context, trust deteriorates quickly.

The clinician hears: “They only care about money.”

What they often do not see is that sustainability is what allows the mission to continue in the first place. Likewise, executives sometimes view clinician concerns as resistance or emotion, when in reality those clinicians are sending signals from the bedside that operators and finance leaders cannot see from conference rooms, spreadsheets, or board decks.

The clinical leaders who become effective are the ones who move fluidly between those worlds without losing credibility in either. That requires humility, because both sides will correct you regularly if you are listening honestly.

Early in my leadership journey, I struggled to build that bridge. Even now, the bridge-building is most of the work. Finding outcomes hospital administrators can support while also advocating for the success and stability of the clinical team is central to operational leadership.

When done well, that bridge creates stability. Stability in staffing. Stability in patient care. Stability in facility relationships. Stability in financial performance.

I have many examples from the early days of YPS Anesthesia where a department of CRNAs and physicians needed support, hospital administration was on a different page, and the department was at risk of fragmenting. The issue was financial in some cases, structural in others, relational or communication-based in others. Learning to find an outcome where everyone could move forward together has been one of the most gratifying parts of leadership, and one of the most important drivers of business success. Many organizations fail not because the clinicians are poor or the administrators unreasonable, but because no one translated between the two.

This is why the transition from clinical practice to administrative leadership requires more than ambition. It requires humility, curiosity, and the discipline to stop proving you are the smartest clinician in the room and start proving you can help the room make better decisions.

The goal is no longer to personally deliver the perfect anesthetic. The goal is to build the teams, systems, and cultures where excellent care happens reliably, repeatedly, at scale.

That is the real transition.

Not from clinician to administrator. From expert doer to builder of people, systems, and trust.

For those willing to make that transition, the impact extends far beyond any single room, any single case, or any single day in practice.

— Tracy

Tracy Young's version of this piece appears on his Substack at tracypyoung.substack.com.

Past the Door’s paid tier opens Monday, June 8. The first paid post lands Friday, June 12. Founder pricing — $6/month or $60/year — runs through July 7.

I sit down with them in the waiting room. I am the anesthesiologist. The surgeon will not be out for another hour, and there are questions the family did not know how to ask the surgical team during the consent conversation earlier. I translate. I draw a small picture on the back of a hospital form showing the new liver in place and the old liver out. I explain the meaning of the numbers on the monitor when the patient gets to the ICU. I tell them what the next twelve hours typically look like and which of those hours are the ones that worry the team most. Their questions slow down, and then they stop. The room is different than it was when I sat down.

Most readers will never sit in that room. They also will never sit in the operating room I just came from, where six clinicians worked through the night while their patient could not see them and his family could not enter. That OR is not the only room those readers cannot see.

There is the boardroom of a large non-profit health system, where the compensation committee approves the executive package against a market study the rest of the organization will never see. There is the executive office a floor below it, where workforce planning runs into the limits of how many nurses and physicians the country is actually graduating each year, and where the conversation either turns into a problem or turns into a plan. There is the credentialing committee, where the existing physicians on staff decide who joins them and where the names available to do the work get fewer every quarter. There is the peer review committee, where a physician’s clinical work is examined by their colleagues behind a closed door, and where the lessons of a hard case become the standard a department is held to. There is the conference room, where a payer and a health system negotiate the unit prices that will quietly determine, eighteen months later, how many nurses are at the bedside on a Tuesday night. There is the C-suite succession meeting where the question of who replaces the CEO when he retires gets decided long before the rest of the organization knows there is a question. There is the M&A meeting where a community hospital becomes a chain asset. There is the regulatory hearing room, where a federal agency writes a rule that will, twelve to eighteen months later, change which procedures can be done in which settings and who gets paid for them.

These rooms are not secret in any movie sense. The decisions made in them are not malicious or hidden. The rooms are simply not open to the people whose work and lives are most directly affected by what happens inside them.

I have spent more than two decades inside both kinds of rooms. The clinical ones, in the operating rooms and the ICU and the holding bay and the recovery unit. The administrative ones, in large health system leadership, and now in my role as Chief Clinical Officer at Essential Anesthesia Management. I am still in both. People sometimes ask why I would leave the bedside for the boardroom, a move some call “becoming a suit.” I have not left. The two are different kinds of work, and they are complementary. On a clinical day, the work is direct and immediate. It is the patient in front of me, the family in the waiting room, the team around the operating table. In the executive rooms, the work is a step removed: the conditions that determine what every team in the system can do at the bedside. I provide patient care a few shifts a month because there is nothing more grounding than an interaction with a patient and family on what is often one of the worst days of their lives. I sit in the executive rooms because the decisions made there determine how many of those interactions are possible, how well the people doing them are supported, and how long the system that makes them possible can keep operating.

This newsletter writes from those rooms.

It does not write about them in the gossip-column sense. It does not name and blame. It does not traffic in the kind of healthcare commentary that depends on outrage to hold a reader’s attention. It writes plainly and specifically about what happens in the rooms most readers do not enter, and why those things matter for the patients, clinicians, and families who live with the downstream effects.

The discipline of this writing is straightforward, and it is worth saying aloud at the start so the reader can hold me to it. I will credit by name the leaders, clinicians, and operators whose work I respect. I will not publicly name and critique colleagues or former employers; that work belongs in private conversation, not in a public forum. I will sit with complexity rather than pretend it does not exist. I will share the strongest counterargument to my position before answering it. If I change my mind on something I have argued for in print, I will say so, and I will explain why. I will not exaggerate for effect. I will not lean on absolute language to compensate for an argument I have not earned. Solid arguments do not need formatting to land well, and I will keep my hand off the bold key as much as I can.

A short preview of where the writing is going next.

I plan to write about the workforce cliff that healthcare is already starting to feel. The story most people hear is about a shortage of interest in clinical careers. The actual problem is closer to the opposite. In many of the relevant training programs, qualified applicants consistently outnumber seats, and the binding constraint is not interest or aptitude. The constraint is clinical training capacity, the number of teaching sites and clinical faculty the country can actually field, and the federal and state policy choices that determine how that capacity is funded and approved. That is a different problem than the one most leaders are solving for, and it has different solutions.

I plan to write about executive compensation in non-profit health systems. There are structural features of the non-profit construct, written into federal tax policy and overseen unevenly at the state level, that make it possible for a senior executive’s total compensation to run five or ten times that of the median nurse at the bedside in the same hospital, and to do so with less public visibility than equivalent compensation would receive in a for-profit setting. I am not arguing the non-profit construct is fundamentally broken. I am arguing the construct has features that allow executive compensation to scale faster than the mission’s reach into the communities the institution was built to serve, and that the same construct supports services for-profit systems will not provide. Both of those things are true. The conversation we are not having is about the features themselves.

I plan to write about leadership development as legacy work. One of the most important tasks of a senior healthcare leader is to develop the next generation of leaders to be better than we are, to think and plan and listen more carefully than we did, and to know we have done the work when those we are developing prove they are better positioned than we are to address the problems of the next decade. We are successful when those we are developing put us out of a job. The reason that line freezes the room is that most leaders are still measuring success by how long they hold their seat, not by who they have ready to take it.

The transplant case ended well. The patient was extubated a few hours after arriving in the ICU. His wife thanked the team while still holding the same paper cup of coffee, and every question she had walked in with had an answer. The room she had sat down in at midnight was a different room when she stood up to leave.

Most of healthcare’s rooms close before that kind of moment can happen in them. The work of this newsletter is to hold the door open long enough for the reader on the other side to see what happened inside, and to walk away understanding it.

The pieces that follow will trust the reader to hold complexity, decline the easy reach for outrage, and arrive at a regular rhythm whether the news cycle is hot or quiet. They will be uneven in topic and consistent in discipline.

If that is the kind of writing you want in your inbox, I am glad you are here.

A free post most weeks, on healthcare leadership, the systems we run, and the policy choices that quietly shape both. A paid post every other week, opening at Week 4, that goes deeper than the free posts can. The occasional argument I would not be able to make if I had not been in the rooms myself. Plain-spoken. Sharp on specifics. Constructive over corrosive.